香港, 2026年4月28日 - (亚太商讯 via SeaPRwire.com) - 4月28日，迈威（上海）生物科技股份有限公司（02493.HK，简称“迈威生物”）成功在香港联合交易所主板挂牌上市，成为又一家“A+H”两地上市的生物科技公司，亦是首家AtoH的18A公司。迈威生物本次全球发售4713.02万股H股，香港公开发售部分超额认购481.71倍，市场反响热烈。强劲的认购态势不仅为发行提供了稳固支撑，也折射出市场对于迈威研发管线与商业化前景的集体看好。迈威生物是一家具备创新研发及端到端产业化能力的中国制药公司。其核心产品9MW2821（靶向Nectin-4）在中国尿路上皮癌临床开发进度仅次于Padcev，且为全球首款进入宫颈癌关键III期试验的同靶点ADC。该产品已获得FDA三项快速通道认定及一项孤儿药资格认定，并获国家药监局两项突破性疗法认定。公司正同步推进该产品针对多项适应症的III期临床试验，计划于2027年提交尿路上皮癌和宫颈癌的NDA申请。若进展顺利，9MW2821有望成为中国首款覆盖多个实体瘤适应症的Nectin-4 ADC，潜在市场空间巨大。迈威生物已有君迈康(R)、迈利舒(R)、迈卫健(R)及迈粒生(R)四款产品实现商业化。2025年公司总收入达6.59亿元人民币，同比增长230%。对外授权合同总金额超过20亿美元，贡献显著。公司与Disc、Calico等国际药企达成的许可协议已带来可观的首付款和里程碑付款，充分验证了其技术成果的国际化变现能力。公司的生产端亦具备国际标准。江苏泰州生产基地符合中国GMP标准及欧盟EMA GMP标准，上海金山生产基地亦符合欧盟EMA GMP标准，为后续产品放量提供保障。迈威生物凭借其差异化的ADC管线及已兑现的商业化能力，加速推进核心产品的上市进程，在全球肿瘤及年龄相关疾病领域持续巩固其竞争优势。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月28日 - (亚太商讯 via SeaPRwire.com) - 2026年4月24日，旭阳集团有限公司（简称"旭阳集团"）与杭氧集团股份有限公司（简称"杭氧集团"）在杭州正式签署战略合作协议。双方将立足京津冀雄和长三角区域，面向全国，在氢能供应体系、高端装备国产化、技术创新及产业投资等领域开展全方位、深层次合作，共同推动我国氢能产业高质量发展。旭阳集团在工业副产氢领域拥有超过30年深厚积累，是全球最大的独立焦炭生产商及供应商；全球最大焦化粗苯加工商、第二大高温煤焦油加工商和己内酰胺生产商(按产能计)，亦是中国最大的焦炉煤气制甲醇生产商和京津冀最大的高纯氢供应商(按产量计)，中国旭阳集团（1907.HK）2019年3月成功在香港联交所主板上市，已形成覆盖"制-储-运-加-用+研"的完整氢能产业链。杭氧集团股份有限公司（002430.SZ）2010年在深圳证券交易所上市，是世界一流的空分设备和低温石化装备供应商，中国气体的产业开拓者和引领者，亦是国内第一台空分设备制造者；其大型、特大型空分设备产量和销量全球第一，总体技术达到国际领先水平，在气体运营及氢能技术研发方面具备领先优势。此次合作是双方优势资源的战略级整合，将旭阳氢源基础与应用场景，与杭氧的装备技术及气体产业能力深度融合，为氢能全产业链生态建设注入强劲动力。聚焦三大合作方向，释放协同发展新动能本次合作将重点围绕氢能销售与供应体系的共建、高端装备国产化应用，以及技术创新与产业化落地展开。双方将通过业务对接与资源协同，构建"液氢生产基地+区域储氢枢纽+加氢站网络"三级供应体系，共同拓展工业、交通、电子、医药、航天等终端市场。同时，双方将联合推进氢能领域关键装备与系统的国产化进程，并在旭阳定州氢能生产基地共建氢能装备测试与技术创新中心，聚焦液氢及加氢站核心部件的验证与攻关，携手申报国家级科研项目及行业标准。为进一步深化合作，双方还拟共同出资设立合资公司，主营氢气/液氢销售、氢能装备制造及技术服务，加速科技成果的产业化落地。合作前景：从资源优势迈向全链引领此次战略合作，标志着旭阳集团氢能产业正加速从"资源优势"向"全链优势"跃升。通过与杭氧集团的强强联合，旭阳将有效补齐在高端装备和气体运营网络方面的关键环节，显著提升氢能产品的市场覆盖能力与流通效率，并借助国产化装备的规模化应用，降低全链条成本，增强核心竞争力。对于杭氧集团而言，合作将助其从传统空分及低温装备领域，深度切入工业副产氢这一丰富的氢能源头，拓展液氢及高纯氢的应用场景，抢占氢能装备与气体服务的市场先机。面向未来，双方将以此次合作为起点，构建可复制、可推广的氢能产业生态。未来合资公司的设立更将为双方带来长期稳定的业务增长极，推动旭阳集团从焦化龙头向全球领先的清洁能源解决方案提供商加速转型，同时也助力杭氧集团实现从装备制造向"装备+服务+运营"的产业链延伸。在国家"双碳"目标的引领下，旭阳与杭氧的携手，将为我国氢能产业的高端化、规模化和国际化发展树立新的标杆。杭氧集团党委副书记童俊表示："旭阳集团在工业副产氢及氢能应用场景方面具有独特优势。杭氧将全力支持双方深度合作，共同推动我国氢能产业迈向高端化、规模化、国际化。"旭阳集团高级副总裁张英伟表示："杭氧集团在低温装备和气体运营方面拥有世界级的技术实力。本次合作是旭阳氢能产业的关键跃升，我们将充分发挥互补优势，加快打造氢能产业生态，助力国家‘双碳’目标实现。"关于战略合作协议，双方已建立高层沟通机制和联合工作小组，确保合作高效落地。未来，旭阳集团将继续秉持开放、协同、共赢的理念，携手产业链优秀伙伴，为构建清洁低碳、安全高效的现代能源体系贡献旭阳力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the biopharmaceutical industry is ushering in a golden cycle of development. As a representative enterprise in China's innovative pharmaceutical sector, Mabwell (Shanghai) Bioscience Co., Ltd. (“Mabwell” or the “Company”, stock code: 02493.HK) has seized industry development opportunities by leveraging its profound R&D foundation, integrated whole-industry-chain advantages, and forward-looking global layout. Today, it officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX), joining the biopharmaceutical sector of the Hong Kong stock market and opening a brand-new chapter in its international development.Reportedly, founded in 2017, Mabwell is a leading domestic innovative pharmaceutical enterprise, possessing premier innovative drug R&D capabilities and end-to-end whole-industry-chain capabilities that span from drug discovery to commercial sales. Since its establishment, the Company has been deeply engaged in therapeutic areas for major diseases such as oncology, immunology, ophthalmology, and orthopedics, and is committed to providing safer and more efficient innovative treatment solutions for patients worldwide.Rich and Diversified Product Pipeline Builds Core Competitive BarriersA rich and promising product portfolio serves as the core pillar for Mabwell’s steady development, as well as its key advantage in seizing first-mover opportunities in the market. With a long-term, deep-rooted presence in the innovative drug sector, the Company has built a diversified product pipeline featuring multiple categories and tiers. As of now, Mabwell has 4 commercialized products and 10 drug candidates: 1 in NDA stage,, 1 in preclinical stages, covering multiple high-potential therapeutic areas and supporting long-term growth.Mabwell’s self-developed core product, 9MW2821, fully demonstrates the Company’s leading edge in the ADC field. 9MW2821 is the most advanced among all Nectin-4-targeting ADCs for urothelial carcinoma (“UC”) in China in terms of clinical development progress, and only second to the globally blockbuster drug Padcev. Meanwhile, it is also the first Nectin-4-targeting ADC globally to enter the pivotal Phase III clinical trials for cervical cancer (“CC”), and triple-negative breast cancer (“TNBC”), boasting extensive market potential.Beyond 9MW2821, Mabwell continues to advance the R&D of ADC candidates targeting other novel targets and has built a comprehensive ADC pipeline portfolio. Its pipeline includes 7MW3711, an ADC specifically targeting B7-H3 (an immune checkpoint protein), and 7MW4911, an ADC specifically targeting CDH17. This layout further diversifies the Company’s footprint in oncology treatment and steadily consolidates its leading advantages in the ADC track.Notably, Mabwell has also strategically prioritized the layout of product pipelines covering monoclonal antibodies (“mAbs”), TCE bispecific antibodies, fusion proteins and small molecule drugs, fostering a pattern of coordinated development across multiple product categories. Its R&D portfolio includes: 9MW3811, a humanized monoclonal antibody targeting IL-11 for the treatment of fibrosis -related diseases and cancers; 9MW1911, the first domestically developed drug candidate approved for clinical development in China targeting ST2; 9MW3011, a recombinant humanized TMPRSS6 targeting mAb among the leading TMPRSS6-targeting therapies in terms of development status globally; and 6MW5311, the world’s first LILRB4/CD3-targeted TCE bispecific antibody filed for clinical trials. These candidates keep expanding the boundaries of the Company’s innovative drug research and development.Outstanding commercialization capabilities, expanding a global market footprintLeveraging its fully integrated industry chain capabilities and forward-looking commercialization strategy, Mabwell (Shanghai) Bioscience Co., Ltd. has continued to deliver tangible commercialization outcomes. In 2025, the Company’s Junmaikang® obtained marketing approval in Indonesia, while Mailisheng® and Maiweijian were approved for commercialization in Pakistan, marking steady progress in its international commercialization efforts.Since 2022, the Company has actively expanded overseas collaborations, entering into multiple landmark international partnership agreements and securing corresponding revenue-sharing arrangements. It has successfully penetrated emerging markets including Brazil, Indonesia, Saudi Arabia, and countries along the Belt and Road Initiative, establishing an extensive global commercial network.In terms of global partnerships, Mabwell has further deepened its international presence. In January 2023, the Company entered into an exclusive licensing agreement with Disc Medicine for 9MW3011, under which it is entitled to receive up to US$412.5 million in upfront payments, milestone payments, and royalties. In June 2025, it reached an exclusive licensing agreement with Calico Life Sciences for 9MW3811, with total potential consideration exceeding US$600 million, including upfront, milestone, and royalty payments. In October 2025, the Company signed an exclusive licensing agreement with Kalexo Bio for a novel dual-target siRNA candidate drug, further expanding the breadth and depth of its international market collaborations.Powerful Technology Platforms Lay a Solid Foundation for Innovation-Driven GrowthPowerful technology platforms serve as the core engine for sustained innovation at Mabwell, and are also pivotal to building differentiated competitive advantages. With deep commitment to technological R&D, the Company has established four core ADC technologies for which we possess proprietary intellectual property rights, providing strong support for the development of innovative drugs.Among these, DARfinity is a self-developed site-specific conjugation process that enables precise drug molecule conjugation; IDconnect is an optimized design of linker molecules that enhances the stability of the linkage between the antibody and toxins; Mtoxin is a class of camptothecin-based novel toxic molecules that are used as the “warhead” in the ADC to kill the targeted cells, providing more potent target cell killing effects; LysOnly is an innovative structure that allows conditional release of toxins, effectively improving the overall safety and efficacy of ADC drugs.These four proprietary technologies serve as the core pillars of our site-specific conjugation ADC development platform, synergistically enabling the Company to develop ADC products with better uniformity, stability, purity, and a superior efficacy and safety profile. This significantly improves pipeline R&D efficiency, allows rapid response to clinical and market demands, and continuously consolidates the Company's leading position in the ADC field.In addition, Mabwell continues to develop and upgrade other core technology platforms, forming a multi-technology synergistic development system. These platforms include the integrated high-efficiency antibody discovery platform and the T-cell engager (TCE)-based bi/tri-specific antibody development platform, among others. The TCE-based bi/tri-specific antibodies developed on these platforms can simultaneously and specifically bind to tumor-associated antigens and the T-cell CD3 epitope, thereby laying a solid technical foundation for the Company's strategic positioning in the field of immunotherapy.From an industry perspective, the global biopharmaceutical sector, as a core segment, has continued to gain momentum in recent years. The global oncology drug market grew from US$143.5 billion in 2019 to US$253.3 billion in 2024 with a CAGR of 12.0%, and is expected to further increase to US$375.9 billion, and US$548.2 billion in 2028, and 2032 respectively, with CAGRs of 10.4% from 2024 to 2028 and 9.9% from 2028 to 2032, respectively. This trend presents substantial growth opportunities for leading industry players like Mabwell, which possess core technologies and a globalized footprint.Driven by in-house R&D, supported by integrated end-to-end capabilities across the entire industry chain, and guided by a long-term global strategy, Mabwell continues to advance steadily in the innovative pharmaceutical sector. Leveraging a robust product pipeline, strong technological expertise, and well-established commercialization capabilities, the Company has built a solid competitive position. Its successful listing in Hong Kong will further accelerate the development of its core products, enhance its commercialization strategy, and strengthen its core competitiveness. This, in turn, is expected to position the Company at the forefront of the biopharmaceutical wave, with strong long-term growth potential that merits close market attention. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - Beijing 51WORLD Digital Twin Technology Co., Ltd. (“the Company”, Stock Code: 6651.HK) announced on 27 April 2026 the first grant of 940,200 restricted share units (RSUs) to 303 employees under its 10-year RSU Scheme, representing approximately 0.23% of the Company’s total issued shares.The underlying shares will be sourced from existing H Shares acquired by the Trust on the secondary market and/or treasury H Shares repurchased by the Company using its own funds. Vesting of the award shares shall be 25% after 12 months from acceptance, and the remaining 75% shall vest in 12 quarterly instalments at 6.25% each until fully vested.The RSU Scheme is intended to align the interests of the core team with the long-term development of the Company and enhance the incentive mechanism for talent attraction and retention. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Saskatoon, Saskatchewan--(ACN Newswire via SeaPRwire.com - April 27, 2026) - Buffalo Potash Corporation (TSXV: BUFF) (OTCQB: BLPTF) (the "Company" or "Buffalo") is pleased to announce the completion of a Preliminary Economic Assessment ("PEA") and concurrent release of its maiden 43-101 Mineral Resource Estimate for its 100%-owned Disley Potash Project (the "Disley Project"), located in Saskatchewan, Canada.The PEA has been filed and can be found under the Company's profile on SEDAR+ (www.sedarplus.ca) and on the Company's website (www.buffalopotash.ca).PEA & Mineral Resource Estimate Highlights Total production of 1,000,000 tonnes per annum (TPA) of K62 granular-grade Muriate of Potash (MOP) and 125,000 TPA of K62 soluble grade MOPAfter-tax NPV(1)(8) of US$1.1B and IRR(1) of 30%US$639M initial CAPEX estimate, including US$128M in contingencyEstimated US$55/t MOP OPEX (Table 4)Measured and indicated tonnage of 1,671.5 million metric tonnes at an average grade of 34.8% KCl, yielding 582 million tonnes of KClOver 50 years of mine life at 1,125,000 TPA based on current resource estimate (Table 2)(2)The advancement of a Feasibility Study ("FS") for Disley East and Disley West (the "HLD Mines") will run concurrent with Initial Production Module ("IPM") construction, with FS completion representing the key decision gate for proceeding to construction of Disley East and Disley West(3)(2) Based on Measured and Indicated resource estimate of 582Mt at 34.8% KCl.(3) The PEA does not constitute a feasibility study and does not demonstrate economic viabilityMr. Steve Halabura P.Geo., Buffalo Chief Executive Officer, commented: "Since founding Buffalo Potash in 2018, the team and I have invested years of disciplined work — geological, technical, and strategic — to systematically unlock the potential of modular selective solution potash mining in Saskatchewan, the key being Buffalo's Disley Project. Having spent my career working in Saskatchewan potash, I had a strong conviction from the beginning that Disley had a substantial resource endowment, and this Mineral Resource Estimate confirms exactly that. The PEA illustrates both low capex per tonne and operating cost per tonne, as well as setting a new environmental standard for how potash production should look in the 21st century — no tailings stored on surface and minimal freshwater usage." Mr. Halabura continued: "The team and I believe the Disley Project represents the next generation of Saskatchewan potash solution mining and are excited to begin development of the Initial Production Module, which will be the first leg of this buildout and is expected to bring soluble-grade potash production online within the next 12 months. During the development of the Initial Production Module, we will also test our patent-pending Vortex Crystallizer, alongside an industry standard crystallizer, which has the potential to significantly reduce the capex of the Initial Production Module and further potential build-outs. With global attention turning to the security of critical supply chains, the urgency to bring reliable, jurisdiction-stable potash production online has never been greater. This is a proud moment for our team, our shareholders, and the stakeholders that have supported us along the way — and we are just getting started."Table 1: PEA SummaryLine ItemUnitsTotal Project Production Rate MOPTPA1,000,000Production Rate Soluble GradeTPA125,000Total Initial CAPEXUS$ million639CAPEX per Tonne CapacityUS$/tonne568Average Unit OPEXUS$/tonne55MOP Price (25-year avg.)US$/tonne393.6(4)Soluble Grade Price (25-year avg.)US$/tonne373.6(5)Pre-Tax NPV(1) (8%)US$ million1,534.67Pre-Tax IRR(1)%35Post-Tax NPV(1) (8%)US$ million1,085.47Post-Tax IRR(1)%30Steady-State Annual RevenueUS$ million442.5Steady-State Annual EBITDAUS$ million251.0 (4) LoM average price of Granular MOP, produced by Disley East and Disley West(5) LoM average price of Soluble Grade MOP, produced by IPMThe PEA is preliminary in nature and includes inferred mineral resources, which are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized.PEA & Mineral Resource Estimate OverviewThe PEA was prepared by Micon International Co Limited ("Micon") in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects and evaluates the development of the Disley Project as a phased potash solution mining operation. The PEA has an effective date of April 15, 2026 and is based on a Mineral Resource Estimate ("MRE") developed concurrently by Micon with an effective date of April 15, 2026, incorporating historical assay data from legacy drilling programs as well as results from Buffalo Potash's 2026 confirmation drill program. The PEA contemplates a phased development approach across three production facilities on the Disley property:The Initial Production Module ("IPM") - is a low-capital entry point designed to bring 125,000 tonnes per year of soluble grade MOP to market;Disley East - a full-scale HLD Mine on the east segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP; andDisley West - a full-scale HLD Mine on the west segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP.Successful construction of the IPM is anticipated to provide technical data used in the completion of the concurrent FS and would, subject to the results from the FS and a positive construction decision, be followed by the potential concurrent development of the Disley East and Disley West HLD solution mines. If fully developed, the Disley Project is designed to have the capacity to produce 1,000,000 TPA of granular MOP and 125,000 TPA of soluble grade MOP ("Full Production Capacity").The MRE indicates a resource base that substantially exceeds the project's current design requirements, which, if successfully developed, would position the Disley Project as a long-life asset. This is consistent with the generational mine lifecycles typically associated with Saskatchewan potash operations, though there is no certainty that resources will be converted to reserves or that any particular mine life will be achieved.Table 2: Mineral Resource EstimateCategoryTonnage (Mt) Avg KCl GradeAvg K2O GradeKCl (Mt)K2O (Mt)Measured399.734.82%22.00%139.287.9Indicated1,267.434.84%22.01%441.5278.9Inferred2,663.234.96%22.08%930.9588.1 Table 2 Notes:The effective date of this MRE is April 15, 2026.Dr. Ryan Langdon, Ph.D, CGeol, of Micon is the QP responsible for this MRE.The MRE has been classified in the Measured, Indicated and Inferred categories.An average specific gravity (SG) value of 2.08 g/cm3 was used.Conversion between KCl and K2O was made using the formula KCl = K2O * 1.583The MRE used economic assumptions for HLD mining. A deduction was made to account for the presence of mining anomalies not detected by existing drill holes and seismic lines. The values used are 5% for Measured, 9% for Indicated and 25% for Inferred.The block model supporting the resource is orthogonal and has a block size of 50 m x 50 m x 0.9 m.The mineral resources described above have been prepared in accordance with the current Canadian Institute of Mining, Metallurgy and Petroleum Standards and Practices.Numbers have been rounded to the nearest million tonnes. Differences may occur in totals due to rounding.Mineral Resources are not Mineral Reserves as they do not have demonstrated economic viability. The quantity and grade of reported Inferred Mineral Resources are uncertain in nature and there has been insufficient exploration; however, it is reasonably expected that a significant portion of Inferred Mineral Resources could be upgraded into Indicated Mineral Resources with further exploration.Micon's QP has not identified any legal, political, environmental, or other factors that could materially affect the potential development of the mineral resource estimate.Figure 1: Core Samples from the 7-10 Hole on the Disley ProjectTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/12107/294332_592822e3642ebbb0_001full.jpgMining MethodBuffalo intends to develop the Project using solution mining, a well-established approach that has been successfully deployed across Saskatchewan for more than 50 years. Solution mining is widely recognized as a reliable and efficient technique for extracting potash from laterally continuous deposits, notably used at both neighboring properties of the Disley Project — the K+S Bethune mine and the Mosaic Belle Plaine mine.Building on this proven foundation, Buffalo holds a patent on an enhanced solution mining approach known as Horizontal-Line-Drive Selective Solution Mining ("HLD Mining"), which is the installation of commercially proven oil and gas injection systems within horizontal wells. This method is designed to optimize efficiency, reduce overall capital intensity, and significantly limit freshwater requirements, while remaining grounded in the principles of traditional solution mining.Following underground dissolution, potash-rich brine is recovered to surface and processed through crystallization, drying, and compaction to produce a finished potash product ready for local delivery or export via existing road and rail infrastructure that currently runs adjacent to the Disley Property.Initial Capital Expenditure (CAPEX) The initial capital cost estimate has been prepared in line with the Class 4 definition outlined by AACE International standards, with a contingency of 25% applied to the IPM, Disley East, and Disley West components.Mechanical equipment represents the largest component of initial capital expenditure at approximately 38% of Total Project initial CAPEX. For Disley East and Disley West, the mechanical scope encompasses the full processing train required to produce export-grade granular MOP, including crystallization, debrining and drying, compaction and glazing, soluble product screening, and product storage and loading. For the IPM, the mechanical scope includes a crystallizer, pumps, tanks, pipework, centrifuge, dryer, and baghouse. Total initial capital expenditure across all three facilities is US$639 million, as summarized in the table below.Table 3: Initial CAPEX SummaryDescription IPMDisley EastDisley WestTotal Project(US$ million)(US$ million)(US$ million)(US$ million)Site Works0.711.311.323.3Concrete-5.65.611.2Structural Steel1.29.39.319.9Mechanical15.1113.3113.3241.7Piping0.214.914.930.0Electrical-15.015.029.9Instrumentation0.12.92.95.9Architecture0.019.619.639.2Minor Mechanical4.72.42.49.4General Construction1.413.313.328.0Indirects-36.136.172.3Contingency5.860.960.9127.7Total Capital Expenditure(6)29.2304.7304.7638.6  (6) For modelling purposes, the total capital expenditure estimate for the PEA assumes use of an industry standard crystallizer instead of Buffalo's patent-pending Vortex Crystallizer.Sustaining capital of US$483 million (US$17/t MOP) over the life of mine comprises an annual provision of 2% of original fixed plant and surface infrastructure costs, plus US$10/t MOP for the drilling, completion and tie-in of replacement wells — the dominant component of sustaining capital — based on each set of three wells yielding 500,000 tonnes over an approximate 5-year useful life.Operating Expenses (OPEX)Buffalo Potash's estimated operating cost of US$55/t MOP reflects the structural advantages of operating in Saskatchewan, a mature potash jurisdiction with competitive industrial energy rates, an established skilled workforce, and existing road and rail infrastructure adjacent to the Disley Property enabling low-cost delivery to both domestic and export markets. Buffalo management anticipates these fundamentals position the Disley Project to be among the lowest-cost potash producers upon reaching full production.Table 4: OPEX SummaryItemDescription1,125,000 TPA(US$ million)IPM Contingency$14.49/t applied to IPM production only1.8Wellfield Power500 Hp at $0.063/kWh1.8Processing Power19,356 Hp at $0.063/kWh18.0Drilling$25,000/day; 45 days/yr0.1Pipes, Pumps, ValvesSteaming & general maintenance0.8InstrumentationMonitoring & controls0.4Labour32 staff7.8Natural Gas$386/1000m³ incl. carbon tax19.6Maintenance5% of major equipment capital5.4ReagentsDedust oil & anticake amines2.0Water$2.20/m³; 45 m³/hr1.3General & Admin SupervisionManagement & safety1.9Admin SuppliesOffice & admin supplies0.8Total Annual OPEX61.7OPEX US$/t MOP55 / tonne Economic AssumptionsThe economic analysis evaluates the Disley Project as a phased development consisting of the IPM to establish early cash flow, followed by the full-scale HLD Mine comprising Disley West and Disley East. The IPM was evaluated as a standalone project, with the HLD Mine (Disley East and Disley West) assessed on an incremental basis and in combination with the IPM as an overall project. A Discounted Cash Flow ("DCF") model was constructed with the following assumptions:All costs and revenues are expressed in constant, first quarter 2026 money terms, with no provision for escalation or inflation;Capital and operating cost estimates denominated in Canadian dollars have been converted to US dollars at an exchange rate of CAD 1.38 per USD;A discount rate of 8% has been applied on an all-equity basis;The pre-tax results presented include the Saskatchewan Potash Production Tax (PPT) and royalties but exclude federal and provincial corporate income tax. The after-tax results include corporate income tax (Saskatchewan 12%, Federal 15%);The IPM ramps up over 3 months at 50% of nominal capacity; Disley West and Disley East have a 6-month ramp-up period at 50% of capacity, with the Disley East being deferred by a 3-month offset from the West Section;It is assumed the IPM is scheduled to begin construction July 2026 with commercial operations starting January 2027;It is assumed that a positive construction decision will be reached on Disley West and Disley East. Disley West is scheduled to begin construction July 2027, with operations beginning July 2029. Construction at Disley East is scheduled to be the final facility developed, with construction beginning October 2027 and operations beginning October 2029;Soluble grade MOP produced by the IPM is sold locally, incurring a transport cost of US$10/t compared to US$43/t for export grade granular MOP railed FOB Vancouver; soluble grade MOP is priced at a US$20/t discount to granular, reflecting a life-of-mine average of US$373.6/t versus US$393.6/t FOB Vancouver;In addition to MOP, the IPM will produce 50,000 m³ per year of KCl brine that may be attractive to regional oilfield services customers at an average transport cost of US$10/m³;Payback period is measured from the start of construction to the point at which cumulative cash flow turns positive; andAlthough the project's mine life is anticipated to extend beyond a 25-year time frame, the NPV(1) and IRR(1) calculations reflect a 25-year "LoM" period.The primary input parameters for the DCF model are outlined in the table below.Table 5: Summary of Inputs for Economic AnalysisInput ParametersUnitValueEvaluation Base Date - IPMDate2026-07-01Evaluation Base Date - Disley East & Disley WestDate2027-07-01Sales: HLD Mine MOP Sales (granular)TPA1,000,000Sales: IPM MOP (soluble)TPA125,000Sales: KCl Brinem3/yr50,000Price: Granular MOP (FOB Vancouver) 25-year averageUS$/t394Price: Soluble MOP 25-year averageUS$/t374Price: KCl BrineUS$/m343Transport Costs: Granular MOPUS$/t43Transport Costs: Soluble MOPUS$/t10Transport Costs: KCl BrineUS$/m310Corporate Tax (Sask. + Canada)%27%Contingency for CAPEX%25%Discount Rate%8%NPV calculationYears25 The Disley East and Disley West mines have a start date of construction later than that of the Initial Production Module, and their IRR(1), NPV(1) and Payback periods are all calculated from that later date, while the overall Project results reflect the start date of the IPM. The individual IPM phase has a payback period of 1.1 years, while Disley East and Disley West each respectively have payback periods of 2.9 years. The total Project payback of 4.7 years reflects an earlier calculated start date at the time of first production at the IPM, prior to first production from Disley East and Disley West.Table 6: Summary of OutputsMetricUnitTotal ProjectInitial CAPEXUS$ million639OPEXUS$55 / tonnePre-Tax NPV(1) (8)US$ million1,534Pre-Tax IRR(1)%35%Post-Tax NPV(1) (8)US$ million1,085Post-Tax IRR(1)%30% The Disley ProjectThe Disley Project is located approximately 50km northwest of Regina and covers 10,610 hectares (Crown and Freehold mineral rights). The property is situated immediately adjacent to the east of the K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine — both of which are amongst the largest producing potash solution mines in the world. In the opinion of management, the Disley Project is in one of the most favorable areas of Saskatchewan for potash solution mining (see Figure 2) as evidenced by the success of these neighboring projects(6).Figure 2: The Disley Property Situated Amongst Major Potash Solution Mines(7)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/12107/294332_592822e3642ebbb0_002full.jpgAbout Buffalo PotashBuffalo Potash is an emerging Saskatchewan-based potash developer pursuing a modular approach to selective solution mining through its patented Horizontal Line-Drive (HLD) technology. Buffalo is advancing the Disley Project — located next to several of the most prominent currently producing potash solution mines in the world — with the objective of establishing capital-efficient, lower-impact potash production in one of the world's leading potash jurisdictions.Qualified PersonThe scientific and technical information contained in this news release has been reviewed and approved by Douglas F. Hambley, PhD, PE, P.Eng., PG, an independent consultant of the Company and Qualified Person as defined under NI 43-101 Guidelines. Dr. Hambley is a globally recognized expert in potash geology and mine development and has assisted Micon in their preparation of the MRE and PEA.All related and pertinent information has also been reviewed for this news release by Jared Galenzoski, P.Geo, FIMMM as an independent consultant and Qualified Person as defined under NI 43-101. Mr. Galenzoski is also an expert in several potash-related fields and has assisted Micon in their preparation of the MRE and PEA.Technical Report and Qualified PersonsFor more information in respect of the Disley Project, including with respect to key assumptions, parameters, and methods used to estimate the MRE, data validation and QA/QC procedures, and the basis, qualifications and assumptions for the PEA, please refer to the entirety of the Technical Report prepared by Ryan Langdon, PhD, P.Geol.; Jack Nagy, PEng; Christopher Jacobs, CEng., MIMMM; and Richard Thompson, CEng, MiChemE. Each of the aforementioned persons is considered a "Qualified Person" for the purposes of NI 43-101 and has reviewed and approved the scientific and technical disclosure contained in this news release. No limitations were imposed on their verification process. Readers are cautioned to review the entirety of the PEA as it contains additional disclosures material to the matters discussed in this press release.Notes(7) The K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine (together, the "Adjacent Properties") may each be considered an "adjacent property" (within the meaning of NI 43-101) to the Company's Disley Project. The Company does not have any interest in either of the Adjacent Properties. The Company believes this context is useful in illustrating the proven endowment of the district, while noting that mineralization on adjacent or nearby properties is not indicative of mineralization on the Company's Disley Project. There is no guarantee that the Disley Project will yield comparable results to any of these mines.ContactSteve Halabura, P.Geo. | Chief Executive Officer & DirectorEmail: steve@buffalopotash.ca | Phone: 1-306-220-7715(1) Non-GAAP Financial MeasuresNet Present Value ("NPV") and internal rate of return ("IRR") are forward-looking financial measures used by management to evaluate the economic potential of the Disley Project, as estimated in the PEA. These measures do not have standardized definitions under IFRS and may not be comparable to similar measures disclosed by other issuers.NPV represents the sum of discounted future after-tax cash flows projected over the 25-year evaluation period at a discount rate of 8%, net of initial and sustaining capital expenditures. The most comparable IFRS measure is net income (loss); however, NPV is a forward-looking measure that reflects projected future cash flows and cannot be directly reconciled to historical net income. IRR represents the discount rate at which NPV equals zero across the project's projected cash flows.These measures should not be construed as alternatives to net income, comprehensive income, or cash flows from operations as determined in accordance with IFRS. Readers are cautioned that these measures reflect PEA-level estimates and are subject to the risks and uncertainties disclosed under "Forward-Looking Information" below.Forward-Looking InformationThis news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-looking information is generally identifiable by the use of words such as "believes," "may," "plans," "will," "anticipates," "intends," "could," "estimates," "expects," "forecasts," "projects," "targets," "schedules," or similar expressions, and the negative of such expressions.Forward-looking information in this news release includes, but is not limited to, statements regarding: the results, assumptions, and projections contained in or derived from the PEA and Mineral Resource Estimate for the Disley Project, including projected production rates, capital and operating costs, NPV, IRR, payback periods, and mine life; the anticipated timing and phasing of construction and commercial production for the IPM, Disley East, and Disley West; the Company's ability to secure permitting, financing, and all necessary regulatory approvals; the anticipated cost and technical performance of the HLD Mining method; expectations regarding MOP and soluble grade potash pricing, transportation costs, and market access; and the Company's broader development plans and strategy for the Disley Project.Forward-looking information is based on management's reasonable assumptions, estimates, analysis, and opinions made in light of its experience and perception of historical trends, current conditions, and expected future developments, as well as other factors that management believes are relevant and reasonable in the circumstances as of the date such statements are made. Key assumptions underlying the forward-looking information include, but are not limited to: the accuracy of the Mineral Resource Estimate and PEA, including geological, engineering, and cost assumptions; no material adverse changes to commodity prices, exchange rates, or tax and royalty regimes; the availability of financing on acceptable terms; the Company's ability to obtain necessary permits and approvals on anticipated timelines; and the continued availability of equipment, personnel, and infrastructure.Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied, including: the inherent uncertainty of PEA-level studies and the possibility that actual capital costs, operating costs, and production rates differ materially from estimates; changes in potash or fertilizer market prices; fluctuations in currency exchange rates, particularly the Canadian dollar relative to the US dollar; the risk that permitting, financing, or regulatory approvals are not obtained on anticipated timelines or at all; risks related to the development, commissioning, and operation of novel mining technology; risks inherent to solution mining operations; and general business, economic, competitive, political, and social risks and uncertainties.A PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as Mineral Reserves. There is no certainty that the PEA will be realized. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. The forward-looking information contained herein is made as of the date of this news release, and the Company disclaims any obligation to update or revise such information except as required by applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294332 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - Standard Chartered and the Hong Kong Trade Development Council (HKTDC) jointly released the latest Standard Chartered Greater Bay Area Business Confidence Index (GBAI), revealing that business sentiment among companies in the Greater Bay Area (GBA) remained stable in the first quarter of 2026 despite ongoing geopolitical and trade headwinds, notably oil price shocks and continued repercussions from the Middle East conflict.Maintaining Momentum Amid HeadwindsThe Q1 findings largely captured activity and business sentiment since the Middle East conflict began in late February, which has remained highly uncertain and weighed on overall business and market sentiment.Despite a reduced appetite for expansion amid persistent geopolitical uncertainties, business sentiment remained steady across the GBA. The “current performance” index for business activity in Q1 edged down marginally to 49.9 from 50.3 in the previous quarter, while the “expectation” index moderated to 50.4 from 51. Both indices hovered around the 50-neutral mark, indicating GBA corporates’ resilience, supported by favourable policies announced by the Chinese Government aimed at boosting the domestic economy, which in turn would partially offset the fallout of the Middle East conflict.The “current performance” index came down mainly driven by “raw material inventory”, “fixed asset investment” and “financing scale”. The latter two readings were believed to reflect more cautious sentiment among businesses in light of the Middle East conflict. Meanwhile, “production/ sales”, “prices of finished goods/ services” and “profits” all experienced quarter-on-quarter expansion.The “expectations” index remained modestly positive, despite heightened external uncertainties. “New orders” held steady at 51.5, while “prices of finished good/ services” rose to 58.5. However, “profits” fell below the 50-watershed level, implying surveyed companies did not view price increases as sufficient to offset a likely rise in energy and material costs.Hong Kong to Sustain a Still-solid Growth PaceBy city, Hong Kong is expected to maintain a solid performance going forward. Although both the “current” and “expectation” sub-indices edged down to 52.7, these readings still comfortably stayed in expansionary territory, supported by improvements in “financial services” and “innovation and technology” sectors.Tommy Wu, Senior Economist, Greater China and North Asia, Standard Chartered, said: “In addition to the initial impact of surging global energy and freight costs, there are concerns about second-round impacts, such as higher input costs and weaker global demand. This is aligned with the latest reading, which shows a 2.3-point decline in “new export orders” to 47.5 for “current performance”, indicating a more cautious outlook for export demand. With the prolonged Middle East conflict, we anticipate global energy prices to be higher for longer and the second-round effects to become more visible in the coming months. These will likely weigh on business sentiment and appetite on making fixed investment. Nevertheless, Hong Kong has once again demonstrated its resilience amid market turbulence, and such resilience is expected to attract more global capital into HKD and Renminbi assets as safe-haven allocation.”Demand-boosting Measures Favour GBA BusinessesThe survey also investigated the impacts of a series of supportive policies from the Chinese government aimed at stimulating domestic demand in its thematic section. Among the new policy measures introduced by the Ministry of Finance in January, most respondents cited “loan interest subsidies for small, medium and micro-sized enterprises” (38.4%), “large-scale equipment upgrade subsidies” (36.9%) and “consumer goods trade-in subsidies” (31.7%) as the top domestic demand-boosting policies likely to have the most positive impact on their business.Wing Chu, Deputy Director of Research, HKTDC, said: “Demand-boosting stimulus is generating tangible benefits for GBA companies, helping to cushion external challenges amid the Middle East conflict. Targeted support, including loan interest subsidies, alongside measures aimed at stimulating consumer spending, is underpinning demand and supporting business activity across the GBA. Overall, policy-led demand support continues to serve as a meaningful tailwind for GBA businesses. While cost pressures and market competition remain key concerns, respondents are considering stepping up investment in talent and market promotion to sustain further business growth.”While many respondents believe stimulative policies could benefit their businesses by boosting online sales (36.6%) and reducing operating costs (33.8%), challenges faced by GBA corporates remain. Specifically, 54.9% of respondents identified labour costs as the biggest pressure point for their businesses, followed by rental costs (41.7%) and market competition (33.3%). Zooming into Hong Kong respondents, market competition was viewed as a more pressing challenge than rental costs, likely due to the increase in cross-border travel and change in consumption behaviours in recent years. In these circumstances, 38.7% would prioritise their investment in talent recruitment, followed by market promotion (38.1%) and personnel training (36.7%).About the GBAIThe GBAI is the first forward-looking quarterly survey in the market that looks at the business sentiment and synergistic effects in cities and industries across the GBA. It is compiled based on a survey of more than 1,000 companies in the GBA covering the manufacturing and trading, retail and wholesale, financial services, professional services and innovation and technology sectors. The index enables investors and businesses to better understand the current business climate, gauge future performance prospects and formulate their market strategies for the GBA.Related materialsStandard Chartered GBA Business Confidence Index Report: https://www.sc.com/hk/gba/gba-index-report/HKTDC Research: https://research.hktdc.com/en/article/MjMwNjM2MTgxMQReport and photos download: https://bit.ly/4u3izEMWing Chu, Deputy Director of Research, HKTDC (right), and Tommy Wu, Senior Economist, Greater China and North Asia, Standard Chartered (left), announced the latest GBA Business Confidence Index (GBAI) on 27 April 2026.Media enquiriesCorporate Affairs DepartmentStandard Chartered Bank (Hong Kong) Limited Flora Chiu Tel: (852) 3843 2285 Email: flora.chiu@sc.com   Communications & Public Affairs DepartmentHKTDC Christy LeeClayton Lauw Tel: (852) 2584 4369Tel: (852) 2584 4472Email: christy.wn.lee@hktdc.orgEmail: clayton.y.lauw@hktdc.orgAbout Standard CharteredWe are a leading international banking group, with a presence in 54 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.The history of Standard Chartered in Hong Kong dates back to 1859. It is currently one of the Hong Kong SAR’s three note-issuing banks. Standard Chartered incorporated its Hong Kong business on 1 July 2004, and now operates as a licensed bank in Hong Kong under the name of Standard Chartered Bank (Hong Kong) Limited, a wholly owned subsidiary of Standard Chartered PLC.For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.About HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on  @hktdc and  LinkedIn Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年4月27日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（867.HK/8A8.SG）（"康哲药业"）欣然宣布，近期，康哲药业通过其全资附属公司与Pharmacosmos A/S就异麦芽糖酐铁注射液（"莫诺菲(R)"）和右旋糖酐铁注射液（"科莫非(R)"）签订独家商业化与供应协议（"协议"）。根据协议，康哲药业获得了在中华人民共和国（就本协议而言，不含香港特别行政区、澳门特别行政区、台湾地区）独家商业化产品的权利，Pharmacosmos A/S继续负责生产、供应产品。合作期限为协议约定的生效之日起十五年，到期前双方可友好协商延长。本次合作的两款静脉铁剂均为原研药，已在中国获批上市并纳入国家医保目录。其中，莫诺菲(R)为独家药，是中国首款获批上市的第三代静脉铁剂，具有更稳定的创新矩阵式纳米结构，安全性更优[1]，可一次足量补铁，显著减少输注次数、更快提升血红蛋白水平，提高临床便捷性。另一款产品科莫非(R)为目前中国唯一被纳入国家医保目录甲类，也是唯一被纳入国家基本药物目录的静脉铁剂，临床应用多年，其有效性与安全性已得到累积的临床经验和已发表数据的支持。上述两款产品将形成覆盖全渠道、全场景的静脉补铁产品矩阵，可满足不同层级医疗机构、不同类型缺铁性贫血患者的临床需求，为患者提供更多元化、安全、高效的治疗选择。铁缺乏症/缺铁性贫血患者广泛分布于消化、心内、肾内、妇产、骨科等多个科室，均为康哲药业的优势专科领域，两款产品的加入将与其现有在售产品的专家资源、学术推广网络高效协同，进一步强化康哲药业在贫血治疗领域的整体竞争力，并预期对其业绩产生积极正面影响。关于莫诺菲(R)的更多信息莫诺菲(R)已于2021年1月30日获批，用于治疗口服铁剂无效、无法口服补铁或临床需快速补铁时的缺铁状况。2023年被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》（医保目录）乙类医保。莫诺菲(R) 由纳米颗粒组成，其结构稳定、呈基质样，由铁原子层与短链线性异麦芽糖碳水化合物层交替构成。该结构可实现可控的铁释放，游离铁含量更低，从而有助于形成良好的安全性特征，包括较低的超敏反应和低磷血症风险。莫诺菲(R)可实现单次高剂量静脉输注给药1000mg或更高剂量，而较早的疗法（如蔗糖铁）通常需要多次给药，每次仅100至200 mg。因此莫诺菲(R)一次治疗即可实现足量补铁，减少输注次数，减轻医患负担，并提升输注能力。同时，其低磷血症风险较低，有助于避免骨折等并发症，并支持改善疲劳症状（缺铁性贫血关键症状之一）。关于科莫非(R)的更多信息科莫非(R)为第二代低分子量右旋糖酐铁注射液，于2003年在中国大陆获批上市，用于无法口服铁剂的缺铁病人（如不耐受或口服铁剂治疗不满意），同样可实现单次大剂量足量补铁。科莫非(R)凭借多年临床应用积累，其有效性与安全性已得到累积的临床经验和已发表数据的支持，其甲类医保与基药的双重资质，支持其基层临床补铁的核心地位。关于铁缺乏症和缺铁性贫血铁缺乏症（iron deficiency，ID）和缺铁性贫血（iron deficiency anemia，IDA）是普遍影响儿童、停经前女性（尤其是孕妇）及老年人的全球性健康问题，可对多系统器官功能造成损害，引发生长发育迟缓、行为障碍、认知功能损伤、体能受损、围产期及围手术期并发症等一系列健康问题，亦会严重影响消化系统疾病、慢性肾脏疾病、心力衰竭及肿瘤等慢性疾病的预后[2]。超过10亿人患有缺铁性贫血[3]，使其成为全球疾病负担的主要因素之一[4]。中国第4次营养调查数据显示，居民IDA患病率为20.1%[5]，但医患双方重视程度不足，轻度贫血获诊治者不足20%，极重度贫血者亦仅50%获诊治，ID/IDA存在明显诊断不及时及治疗率偏低的情况[2]。补铁为ID/IDA的常规治疗方式，分为口服补铁与静脉补铁，其中静脉铁剂是口服铁剂不耐受、口服铁剂疗效不佳、临床需快速补铁、患者希望1-2次补足铁量等情境下的重要手段[1,2,6]。但因对IDA重视不足、服药依从性、住院时间、输液便利性等条件限制，加上对静脉铁剂安全性的顾虑导致静脉铁剂使用较为保守。中国真实世界研究显示，IDA患者蔗糖铁使用总剂量均值为511mg，远未达目标剂量1000mg[2]。临床亟需安全性高、补铁疗效佳、可一次足量补铁的静脉铁剂产品。莫诺菲(R)与科莫非(R)构建覆盖全场景的静脉补铁产品矩阵，为缺铁性贫血患者提供分层诊疗选择。关于Pharmacosmos A/SPharmacosmos A/S为碳水化合物化学及缺铁与缺铁性贫血创新治疗领域的全球领先企业。公司凭借在碳水化合物化学与细胞周期生物学的深厚专业积累，致力于针对未被满足的患者需求开发创新疗法，重点关注铁代谢及血液相关疾病。公司成立于1965年，总部位于丹麦，团队由来自英国、爱尔兰、北欧、德国、美国、加拿大及中国的700多名专家组成。凭借优异的产品质量与临床价值，核心铁剂产品已于全球多个国家及地区获批上市并广泛应用，积累深厚技术实力与优质市场口碑。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心肾代谢/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. 中国药理学会药源性疾病学专业委员会. 广东省药学会. 静脉铁剂的临床应用和药学监护专家共识（2024）[J]. 药物不良反应杂志, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃000702. 廖敏婧, 张连生. 铁缺乏及缺铁性贫血规范化诊治[J]. 中华内科杂志, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.5. 李莉娟, 张连生. 缺铁性贫血规范化诊治的若干问题[J]. 中华医学杂志, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.6. 中华医学会血液学分会红细胞疾病（贫血）学组. 铁缺乏症和缺铁性贫血诊治和预防的多学科专家共识（2022年版）[J]. 中华医学杂志, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.More information about Monofer®Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.More information about Cosmofer®Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.About Iron Deficiency and Iron Deficiency AnemiaID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.About Pharmacosmos A/SPharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃000702. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - April 27, 2026) - Copper-gold explorer and hybrid project generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to announce that it will be holding an Investor Webinar Presentation and Discussion on the afternoon of Tuesday April 28th Pacific Standard Time (PST) and morning of Wednesday 29th Australian Eastern Standard Time (AEST).President & Chief Executive Officer, Mr Sam Spring, will update the market on recent and upcoming drill programs, exploration activities and corporate developments across the project portfolio.Both Kincora shareholders and interested investors are invited to attend the webinar and participate in the accompanying Q&A session.Kincora Copper Investor Webinar Details: Canada(Vancouver)US(Dallas)Australia(East Coast)Date28-Apr-202628-Apr-202629-Apr-2026Time4.00PM PST6.00PM CT9.00AM AEST Please note: Registration is required to attend this Zoom format investor webinar.Please register in advance for the Zoom webinar using the following link:https://us02web.zoom.us/webinar/register/WN_IE079ntuTbmoCUiWm6_O5QAfter registering, you will receive a confirmation email containing information about joining the webinar.Questions can be submitted in advance of the webinar to Julia Maguire of The Capital Network via the following email address: julia@thecapitalnetwork.com.auA replay of the webinar will be available on Kincora's website on the following page:https://kincoracopper.com/interviews/About Kincora: Kincora Copper Limited (ASX: KCC) (TSXV: KCC) is an emerging Australia-focused gold-copper explorer with a hybrid project generator strategy.The Company is successfully proving up the prospectivity of its extensive project portfolio, which includes multiple district-scale landholdings and scalable drill ready targets. These assets are located in Australia's Lachlan Fold Belt and Mongolia's Southern Gobi, two of the globe's leading porphyry belts, and the historical Condobolin mining field within the Cobar basin in NSW.The Company has already unlocked over $100 million of potential partner funding for multiple earlier stage and/or non-core porphyry projects. These initial deals have supported over 18,000 metres of drilling and over A$9m of partner funded exploration since late 2024, with management fees and exploration ramping up.Partner discussions are ongoing for its remaining 100% owned flagship projects that are all situated within existing porphyry camps containing over 20-million-ounce gold equivalent resource inventory.By having a significant portfolio of partner funded large porphyry projects, and a very focused capital efficient programs at the Condobolin and other sole funded projects, the Company is seeking to position Kincora as a leading institutional grade explorer in the public Australian and Canadian markets, and the leading project generator on the ASX.The Company's website is: www.kincoracopper.comThis announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345 Laurie Thomas, Strategic Advisor laurie.thomas@kincoracopper.com or +1306 341 3826 Media contactJulia Maguire, Managing Director, The Capital Networkjulia@thecapitalnetwork.com.au or +61 2 7257 7338Executive office Subsidiary office Australia 400 - 837 West Hastings Street C/- JM Corporate ServicesVancouver, BC V6C 3N6, Canada Level 6, 350 Collins StreetTel: 1.604.283.1722 Melbourne, VIC, Australia 3000 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294246 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) today officially opened its seven flagship lifestyle and licensing events. The Hong Kong Gifts & Premium Fair, Home InStyle and Fashion InStyle are being held at the Hong Kong Convention and Exhibition Centre (HKCEC), while the Hong Kong International Printing & Packaging Fair and DeLuxe PrintPack Hong Kong at AsiaWorld-Expo, from today until 30 April. The Hong Kong International Licensing Show and Asian Licensing Conference are running concurrently from today until 29 April, also at HKCEC. Together, the six trade fairs have attracted some 5,600 exhibitors from over 30 countries and regions. HKTDC Executive Director Sophia Chong said: "Hong Kong has long served as the key gateway for global businesses connecting with the Chinese Mainland, playing the role of super connector and super value-adder that bridges the Chinese Mainland's vast market with the rest of the world. Backed by its solid strengths, well developed innovation ecosystem and robust intellectual property infrastructure, Hong Kong is the ideal base for companies to grow their businesses, pursue creativity and innovation, and bring them to commercial fruition."Creative gifts and home products converge; Gifts & Premium Fair and Home InStyle serve as platforms for new product launchesThe Gifts & Premium Fair and Home InStyle continue to offer buyers a diverse range of gifts and home products spanning cultural creativity, sustainability, innovative materials and gerontechnology. Selected highlights from both fairs are brought together on the new "Reimagine" themed floor at HKCEC Hall 5, giving buyers a one-stop overview of the latest global trends in lifestyle homeware and gifting products, while inspiring the industry to envision future product possibilities with fresh perspectives and inspiration.Both fairs are also attracting exhibitors to unveil latest products. Wei Yit Vacuum Flask Manufactory (Booth: 1E-D02), an exhibitor at the Gifts & Premium Fair, is debuting the Camel Brand MINI20 thermos blind box, created by Hong Kong illustrator Pen So and Hong Kong contemporary artist Jerry Cho. With the Camel Brand celebrating its 85th anniversary – the same year as Bruce Lee’s 85th birth anniversary - the exhibitor is also launching another special co-branded thermos.   Home InStyle exhibitor PREN Ltd (Booth: 5E-C20) is making its first-ever public introduction of an infection-prevention mobile toilet — an installation-free, waterless unit requiring no repeated disinfection and no direct contact with waste before and after use, incorporating health monitoring capabilities that seamlessly bring professional care into modern households.Gifts & Premium Fair spotlights design-led giftsThe Hall of Fine Designs at the Gifts & Premium Fair, located at HKCEC Hall 1, once again gathers over 100 local and international exhibitors, featuring premium, design-led products ranging from stationery and home accessories to smart collectibles incorporating the latest technologies. Star Industrial Co., Ltd (Booth: 1C-G03) presents the Red A "Made in Hong Kong" mini-series blind boxes, evoking nostalgic memories of Hong Kong daily life from the 1960s to the 1990s through iconic household items. Moral Team Holdings Ltd (Booth: 1C-E05) introduces the Napier Coded backpack designed for pickleball enthusiasts, crafted from recycled materials and combining sports with sustainability elements.Home InStyle shapes the future of home livingFunded by the Innovation and Technology Commission, Home InStyle this year presents the Gerontech and Innovative Material Pavilion (Booth: 5E-C20), showcasing over 20 local enterprises to feature gerontechnology products, smart living solutions and home products made from innovative materials.Scan Infinity Ltd presents the TechFitX Smart Sports Training System, which uses interchangeable modules and gamified training to help seniors easily build an exercise routine at home. The United Nations University Hub on Humanitarian Innovation and Technology at Lingnan University showcases IntuCREW, a smart power-assist solution designed to reduce the physical burden on caregivers when maneuvering wheelchairs. Other highlights include Sinomax's bionic ultrasonic sleep soother, German Pool's Natural Wellness Machine, and Afontane's self-cleaning bedding system.On the innovative materials front, Lotux International Holdings Co., Limited’sbiodegradable tableware and food containers are made from lotus stems alongside lotus fibre deodorising cat litter; Editecture showcases the reEDIT upcycled chair made from recycled plastic bottles and bottle cap fragments; and Mush Composites presents bio-based tiles produced from agricultural by-products and mycelium for decorative surface applications.Another focal point of Home InStyle, the Cultural and Creative Avenue, gathers design institutions and culturally inspired brands from over 10 countries and regions. Highlights include Indonesia's PT MANAMU ANAIA SUMBA (Booth: 5E-C09A) with its Banoura bracelets; Czech exhibitor Izaak Reich Crystal s.r.o. (Booth: 5E-A14), featuring handcrafted glass with over 150 years of heritage; UK exhibitor Block Design (Booth: 5E-C09B) with double-sided sculptural glass vases; Taiwan exhibitor Karari (Booth: 5E-A18) with incense accessories; and a Macao exhibitor (Booth: 5E-A16) featuring 3D-printed creations. Pantone returns as colour partner, presenting home décor trends through the PANTONE 2026 Colour of the Year "Cloud Dancer".Fashion InStyle showcases global innovation in fashion materialsThe highlighted zone NEXT@Fashion InStyle (NEXT), organised by the HKTDC and sponsored by the HKSAR Government's the Cultural and Creative Industries Development Agency (CCIDA), returns this year to demonstrate how material innovation is driving industry transformation and advancing sustainability across the fashion sector. The Philippines joins as the featured partner, powered by the Philippine Trade and Investment Centre – Hong Kong (PTIC-HK) and the Center for International Trade Expositions and Missions (CITEM). NEXT brings together over 60 exhibitors from across the globe.Exhibitors include Belgium's Bloom Biotech (Booth: 3F-F09), showcasing microalgae leather, the world's first carbon-neutral leather alternative produced through scalable green technology; At Booth: 3F-E04, Finland's Spinnova PLC’s SPINNOVA® is a next-generation textile fibre derived from wood or waste cellulose, and compatible with conventional textile processes and seamlessly blendable with cotton to deliver scalable, recyclable solutions for apparel and beyond; and Vietnam's Thai Son S.P Co., Ltd. (Booth: 3F-F03), has a range of fabrics that includes ramie fabric, a material with over 3,000 years of history and celebrated for its outstanding performance and natural antibacterial properties. The NEXT zone also features exhibitors from Chinese Mainland, Hong Kong, Iceland, Indonesia, Sweden, Thailand, and the United States, among others.Returning as project ambassador, Han Chong, founder and creative director of internationally acclaimed brand self-portrait, leads six local designer brands, each drawing on forward-looking materials selected from eight participating material suppliers to create cross-disciplinary collections. In a first for the project, materials sourced from beyond Hong Kong and Chinese Mainland are incorporated this year, bringing fresh creative momentum to the field of fashion material innovation. For example, design label WILSONKAKI fuses the world's lightest H2 fabric from French supplier Chargeurs PCC, mycelium leather from Indonesian supplier MYCL-Mycotech Lab, and natural fibres from Hong Kong supplier Texwinca Holdings Ltd, to craft everyday pieces that balance lightweight protection with a natural tactile quality through lamination and bonding techniques. The full design collection will be unveiled at tomorrow's NEXT fashion parade.Fashion InStyle also features dedicated zones including the Designer Spotlight, Materials Bazaar, Fashion Accessories, Women in Style, Bridal & Evening Wear, and Athleisure, presenting a rich selection of ready-to-wear and accessories. Glory G International Limited (Booth: 3G-B31) presents its "Resilience" collection  of lightweight suede denim, challenging the conventional perception of heavy denim outerwear; Hong Kong Haiyuan Limited (Booth: 3G-F18) showcases decorative and functional tassel ornaments designed to be attached to handbags, keys and everyday accessories; while Bibi Hanum from Uzbekistan (Booth: 3F-G29) brings traditional silk ikat patchwork wrap skirts.Printing & Packaging Fair and DeLuxe PrintPack Hong Kong present green solutions and high-end craftsmanshipThe Hong Kong International Printing & Packaging Fair and DeLuxe PrintPack Hong Kong,co-organised by the HKTDC and CIEC Exhibition Company (HK) Limited, continue to highlight innovative, eco-friendly and premium printing and packaging solutions. Elements Printing and Packaging Limited (Booth: 3-E01) introduces FSC Transparent Non-plastic packaging products and FSC Glassine Paper Bag, championing plastic-free, recyclable design principles. BSN International Hong Kong Limited (Booth: 3-E02) offers radio frequency identification (RFID) () labels incorporating paper-based inner layers for sustainable design. Guangzhou Xingqiyuan Trading Co., Ltd. (Booth: 3-E11) presents eco-friendly wet-press paper-pulp packaging made from agricultural waste.At DeLuxe PrintPack Hong Kong, Ijen Enterprises Ltd. (Booth: 3-A05) presents 3D rotating music boxes and vintage phonograph gift packaging that integrate music, storage and packaging. Marshallom (Holdings) Limited (Booth: 3-A08) showcases a floral-and-bird paper lantern canister with a dual-purpose design that extends the product lifecycle, alongside the "Victoria Harbour Day & Night" gift box combining light and shadow effects with storage and premium food packaging.Licensing Show launches IP and e-Commerce Support Services zone for the first timeThe Hong Kong International Licensing Show welcomes more than330 exhibitors from Hong Kong, Chinese Mainland and across Asia, showcasing more than 600 brands and intellectual property (IP) projects spanning arts and culture, animation and characters, brand extension, lifestyle, entertainment and sports licensing.  In line with direction of the HKSAR Government's policy to strengthen Hong Kong businesses' competitiveness on cross-border e-commerce, the fair introduces for the first time a dedicated IP and e-Commerce Support Services zone. The zone unites e-commerce platforms, KOLs, marketing and PR firms — including e-commerce platform Digitify Online Growth (Booth: 5G-E04) and marketing firm Matrix Promotion Limited (Booth: 5G-F01) — to support brands and IPs in capitalising on the new opportunities generated by e-commerce growth. Throughout the fair, e-commerce associations will conduct workshops on topics including establishment of e-commerce platforms, global market expansion via e-commerce channels, and livestreaming commerce, equipping the industry to stay ahead of the curve.Headline IPs at the Licensing Show include Potatoz by 9GAG Limited (Booth: 5G-D20), LuLu the Piggy by Toyzeroplus Limited (Booth: 5G-A24), Café de Bollo by Yogurt Studio Ltd. (Booth: 5F-G20), along with Chinese Mainland IP Quby (Booth: 5G-A22), Korean IP LOTTY FRIENDS (Booth: 5F-G36) and Thai IP Warbie Yama (Booth: 5G-A51). Organised by the Innovative Entrepreneur Association (IEA) and sponsored by Cultural and Creative Industries Development Agency (CCIDA) of the HKSAR Government, the Design Licensing and Business (DLAB) Support Scheme again stages the DLAB Hong Kong Pavilion at the Hong Kong International Licensing Show, featuring close to 40 exhibitors showcasing a diverse portfolio of Hong Kong original brands and IPs. The HKTDC also continues its collaboration with the Hang Seng University of Hong Kong, Hong Kong Baptist University and The Hong Kong Polytechnic University, with Hong Kong Design Institute joining as a new partner this year, to present the Hong Kong Licensing Force Showcase, spotlighting the creativity of Hong Kong's emerging talents.The concurrent Asian Licensing Conference invites industry leaders to examine key market developments. Today's programme features Maura Regan, President and CEO of Licensing International, presenting the "Global Licensing Trends to Watch in 2026".  With the FIFA World Cup taking place this year, the conference also welcomes Alessandro Villa, Senior Licensing Manager of FIFA, and Ivan Chan, Founder and CEO of Promotional Partners Worldwide to share the commercial strategies underpinning successful sports licensing. Mark Mao, Executive Vice President and Head of Sales at COVER Corporation will explore how Virtual YouTubers forge connections with GenZ through strategic social media engagement on the next day.Industry seminars and forums explore emerging market opportunitiesTo help industry professionals keep pace with the latest developments, around 60 thematic seminars, buyer forums, product presentations and launch events will be held throughout the fairs, covering trending topics including the silver economy, market trends, culture and innovation, and sustainability.Among the seminar highlights, the Printing & Packaging Fair and DeLuxe PrintPack Hong Kong will present a seminar co-organised by the HKTDC and the Hong Kong Digital Printing Association, titled “From Prompt to Reality: Revolutionizing Visual Design and Printing with Generative AI and Digital Printing”, examining how generative AI and digital printing are driving innovative transformation across the industry. The Gifts & Premium Fair and Home InStyle will host “Re-Gifted: Trends and Triumphs in Sustainable Home & Gift Design”, exploring new directions in sustainable design. Fashion InStyle will stage the seminar “Cultural Fusion in Lifestyle Design: The Surreal Aesthetics of Motifx”, offering the industry the latest market insights, innovative thinking and practical strategies.Photo Download: https://bit.ly/4vQE39EOrganised by HKTDC, the Hong Kong Gifts & Premium Fair, Home InStyle, Fashion InStyle, Hong Kong International Printing & Packaging Fair, Deluxe PrintPack Hong Kong, Hong Kong International Licensing Show and Asian Licensing Conference open today, with the six trade fairs bringing together some 5,600 exhibitors from more than 30 countries and regionsHKTDC Executive Director Sophia Chong delivered the welcome remarks at the opening ceremony of the Hong Kong International Licensing Show and Asian Licensing Conference this morning (27 April)(From left) Commissioner for Cultural and Creative Industries of CCIDA, Drew Lai; Director, Asia Tourism Exchange Centre, Zhang Dong; HKTDC Executive Director, Sophia Chong; Permanent Secretary for Culture, Sports and Tourism, HKSAR Government, Sum Fong Kwang, Vivian; Plan and Policy Analyst Expert Level, Ministry of Culture, Thailand, Narathorn Parndee; and President and CEO of Licensing International, Maura Regan, officiated the opening ceremonyThe Hall of Fine Designs at the Gifts & Premium Fair showcases a premium selection of design-led gifts, including stationery, home products and smart lifestyle items featuring innovative technologyAt Home InStyle, the Gerontech and Innovative Material Pavilion features more than 20 local exhibitors showcasing gerontech products, smart living solutions and innovative materials applied to the homeware and home textilesThe Cultural & Creative Avenue showcases cultural and creative home products from around the world, presenting distinctive brands and designs that celebrate diverse cultural heritagesFashion InStyle this year presents the spotlight zone NEXT@Fashion InStyle, with featured partner the Philippines bringing over 25 exhibitors to showcase local fashion materialsNEXT@Fashion InStyle project ambassador Han Chong (centre) leads six local designer brands in creating fashion collections incorporating selected innovative global materialsBSN International Hong Kong Limited showcases radio frequency identification (RFID) labels with paper-based inner layers at the Printing & Packaging Fair, highlighting both functionality and sustainable designAt DeLuxe PrintPack Hong Kong, Marshallom (Holdings) Limited presents its “Victoria Harbour Day & Night” gift box, a multifunctional design combining decorative lighting, food packaging and storage, inspired by the changing scenery of Victoria HarbourThe Hong Kong International Licensing Show this year introduces for the first time the dedicated IP & e-Commerce Support Services zoneWebsitesHKTDC Media Room: https://mediaroom.hktdc.com/enHong Kong Gifts & Premium Fair: https://www.hktdc.com/event/hkgiftspremiumfair/enHome InStyle: https://www.hktdc.com/event/homeinstyle/enFashion InStyle: https://www.hktdc.com/event/fashioninstyle/enHong Kong International Printing & Packaging Fair: https://www.hktdc.com/event/hkprintpackfair/enDeLuxe PrintPack Hong Kong: https://www.hktdc.com/event/deluxeprintpackhk/enHong Kong International Licensing Show and Asian Licensing Conference: https://www.hktdc.com/event/hklicensingshow/enMedia enquiriesFor enquiries, please contact:Home InStyle, Fashion InStyle, HK Gifts & Premium Fair, HK International Printing & Packaging Fair and DeLuxe PrintPack Hong KongPandagon:Fraser LiTel: 6083 5623Email: pandagon.limited@gmail.comHKTDC’s Communications & Public Affairs Department:Clayton LauwTel: 2584 4472Email: clayton.y.lauw@hktdc.org   HK International Licensing Show and Asian Licensing ConferenceRaconteur:  Molisa LauTel: 6187 7786Email: molisalau@raconteur.hkBetsy TseTel: 9742 7338Email: betsytse@raconteur.hkHKTDC’s Communications & Public Affairs Department:Winnie KanTel: 2584 4055Email: winnie.wy.kan@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - Travelling overseas often feels exciting until unexpected charges appear on your card statement after returning home. Many travellers from Singapore rely on overseas credit cards for convenience, rewards, and security, but international transactions can sometimes include hidden costs that are easy to overlook. From currency conversion markups to foreign transaction fees, these charges can quietly increase overall travel expenses. Understanding how these charges work can help travellers manage spending better and make more informed payment choices while abroad.Below are practical ways that can help minimise hidden fees when using credit cards overseas while keeping travel spending smooth and predictable.Understand foreign transaction fees before travellingForeign transaction fees are among the commonly overlooked charges linked to overseas spending. Many cards issued in Singapore charge a fee of around 3.25% per foreign currency transaction, which may not seem significant at first glance. However, on a holiday budget of SGD 4,000, this fee alone can add SGD 130 to total expenses without obvious visibility during purchases.Reviewing the fee structure of an overseas card before travelling can help travellers estimate actual costs more accurately. Some cards offer reduced or promotional foreign transaction charges, which can help manage overall travel budgets more effectively. Knowing these details in advance may also help travellers decide when card payments make financial sense compared to alternative payment methods.Consider paying in local currency instead of SGDWhen paying overseas, merchants sometimes offer the option to charge the amount directly in Singapore dollars. This feature, known as Dynamic Currency Conversion (DCC), may appear convenient because it shows the final amount immediately. However, exchange rates used in DCC transactions often include markups, which can exceed standard bank conversion fees.Choosing to pay in the local currency allows the overseas card network to process the exchange instead. Card networks typically apply more competitive rates compared to merchant-set conversions. Over multiple transactions, such as dining, shopping, and transport, this can help reduce unnecessary markups.Check card currency conversion ratesExchange rates used by card issuers fluctuate daily and may differ slightly from rates seen on currency apps or news platforms. While the difference per transaction might appear minor, frequent purchases abroad can still affect total spending. For example, a 1% difference on SGD 2,500 worth of spending can translate into roughly SGD 25 in additional costs.Reviewing how an overseas card calculates exchange rates can provide better transparency. Some banks publish their rate calculation methods, allowing travellers to estimate expected charges more accurately.Avoid overseas ATM withdrawals when possibleWithdrawing cash abroad using a credit card can trigger multiple layers of fees simultaneously. These may include cash advance fees, overseas ATM operator charges, and immediate interest accrual starting from the withdrawal date. In Singapore, cash advance fees commonly range between 6% and 8% of the withdrawn amount, with minimum charges around SGD 15.Using an overseas card mainly for purchases rather than cash withdrawals can help reduce these compounded costs. Carrying a modest amount of exchanged currency from Singapore or using debit-based solutions for cash needs may help travellers avoid high-interest situations linked to credit card withdrawals overseas.Watch for hotel and car rental pre-authorisation chargesHotels and car rental companies frequently place temporary holds on credit cards as security deposits. These pre-authorisation amounts can be significant depending on location and booking type. Although not permanent charges, they temporarily reduce available credit limits and sometimes involve conversion adjustments once released.Understanding how pre-authorisation works can help travellers avoid confusion when reviewing statements. Using an overseas card with sufficient credit limits may reduce the likelihood of declined transactions during travel. Checking release timelines with merchants can also help travellers track when funds become available again after checkout.Choose a Travel Credit Card designed for overseas spendingNot all credit cards function the same way internationally. Some overseas card options available in Singapore include travel-focused features, such as lower foreign currency fees, travel rewards, or complimentary insurance coverage. These features can help offset certain costs associated with overseas spending when used strategically.Comparing card benefits based on travel frequency, spending habits, and destinations can help travellers identify options aligned with their lifestyle. A well-matched overseas card may also offer added value through rewards or travel-related privileges, making international spending more predictable overall.Final thoughtsFor Singapore travellers, using an overseas card thoughtfully, alongside awareness of currency conversion practices and transaction structures, can help make international payments more transparent. With a few informed habits, overseas spending can remain convenient while reducing the likelihood of unexpected costs appearing after the journey ends.Disclaimer: This content is published by iQuanti Singapore Pte. Ltd., an external marketer engaged and compensated by UOB Ltd.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - China Chunlai Education Group Co., Ltd. ("China Chunlai" or the "Company", together with its subsidiaries and its consolidated affiliated entities, the "Group", Stock Code: 1969) is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 28 February 2026 (the "Reporting Period").For the Reporting Period, the Group continued to increase the number of students enrolment, and recorded a revenue of RMB956.3 million, representing an increase of 7.4% compared with the same period of last year; gross profit recorded RMB511.6 million, representing an increase of 2.4% compared with the same period of last year; profit recorded RMB429.8 million, representing an increase of 5.7% compared with the same period of last year.During the Reporting Period, the Group recorded tuition fees of RMB874.1 million, representing an increase of 7.4%, boarding fees recorded RMB82.2 million, representing an increase of 6.9%. Besides, the revenue of Group's schools increased: Anyang University recorded a revenue of RMB232.5 million, representing an increase of 12.3% compared with the same period of last year; Jingzhou College recorded a revenue of RMB191.7 million, representing an increase of 12.0% compared with the same period of last year; Jiankang College recorded a revenue of RMB76.1 million, representing an increase of 10.5% compared with the same period of last year; Shangqiu University Kaifeng Campus recorded a revenue of RMB138.0 million, representing an increase of 6.1%;Shangqiu University recorded a revenue of RMB217.7 million, representing an increase of 5.8% compared with the same period of last year.As of 28 February 2026, the number of students enrolled was 116,784, representing an increase of 5.3% compared with the same period of last year. Among which, Jingzhou College had a total enrollment of 21,643, representing an increase of 11.0% compared with the same period of last year; Jiankang College had a total enrollment of 10,808, representing an increase of 10.2% compared with the same period of last year; Anyang University had a total enrollment of 28,897, representing an increase of 9.4% compared with the same period of last year; Shangqiu University Kaifeng Campus had a total enrollment of 16,280, representing an increase of 4.8%;Shangqiu University had a total enrollment of 27,051, representing an increase of 1.8% compared with the same period of last year.The educational philosophies of the Group’s schools and well-developed curricula as well as its high graduate employment rates enable the Group to attract high-quality students who are seeking a pathway to satisfactory employment. For the 2025/2026 school year, the overall yield of five colleges that offer bachelor’s degree programmes (being Shangqiu University, Shangqiu University Kaifeng Campus, Anyang University, Anyang University Yuanyang Campus and Jingzhou College) was 91.55%.The Board of China Chunlai Education Group Co., Ltd. said: “In recent years, private higher education in China has continued to improve, and the number of students in schools has continued to increase. We have seized the opportunity to continuously improve and optimize the curriculum system, build an excellent teacher team, strive to expand the enrollment scale, and promote sustained and steady growth in performance. In the future, we expect to enlarge the capacity of the colleges progressively, continue to increase the total number of enrolled students, and hire teachers with a strong command of their respective subject areas who are open to innovative teaching methods and a caring heart toward students’ well-being, and continuously improve the high-quality curriculum system. With Tianping College becoming a consolidated affiliated entity of the Company, our future performance is expected to maintain steady growth.”About China Chunlai Education Group Co., Ltd.:China Chunlai Education Group Co., Ltd. (1969.HK), is a leading provider of private higher education in China. In September 2018, the Group was listed on the main board of the Hong Kong Stock Exchange. Since the Group was established in 2004, it has grown to operate four colleges in Henan Province and two colleges in Hubei Province, participate in the operation of one college in Jiangsu Province. For the past two decades, the schools under the Group have provided tens of thousands of graduates and talents for construction for the country and socialist society. With a strong passion for education, the Group has seen continuous improvements in educational standards across its curriculum. The Group’s unique educational traits and overall excellence have been widely accredited by authorities and society. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BOSTON, Apr 25, 2026 - (ACN Newswire via SeaPRwire.com) - Peer To Peer Network, Inc. (OTC: PTOP), the first publicly traded digital business card company, today announced that its highly anticipated MOBICARD™ 1.8 platform — featuring integrated revenue-generating capabilities — is expected to be released to app stores within the next 30 days.This upcoming release marks a major turning point for the company as MOBICARD™ transitions from a pure networking tool into a monetized digital ecosystem designed to generate recurring revenue across both consumers and businesses.Built for Revenue — Designed for ScaleMOBICARD™ 1.8 introduces multiple revenue streams, including:Subscription Model for ConsumersFree version supported by adsPremium ad-free version at $1.99/monthAnnual premium plan at $20/yearEnterprise-Level Business MonetizationPaid promotional placements within the appTiered business subscriptions enabling companies to advertise directly to usersLead generation tools for enterprise clientsIn-App Engagement MonetizationTrackable card sharing and user engagement analyticsIncreased visibility for businesses through promoted placementsThese features position MOBICARD as more than just a digital card - it becomes a revenue engine driven by user activity, business adoption, and scalable subscription growth.In addition to monetization, MOBICARD 1.8 includes major upgrades designed to increase engagement and sharing:Seamless one-click sharing functionalityAirdrop abilityFully optimized QR code distributionImproved card navigation and discovery featuresEnhanced UI/UX for a cleaner, more professional lookStreamlined “Share This Card” experience to drive viral growthThe platform is being refined to ensure users can easily connect, share, and expand their networks - while businesses gain powerful tools to reach those users“By integrating subscription models and enterprise tools directly into the user experience, we are building a foundation for scalable growth and long-term value creation,” stated Nicholis Santana Team Technology Leader for Peer To Peer Network.PTOP believes that MOBICARD™ 1.8 represents a critical inflection point, as the platform begins to:Convert user activity into recurring revenue streamsProvide scalable monetization opportunities for businessesIncrease overall platform engagement and retentionWith monetization now integrated into the core user experience, Peer To Peer Network is positioning MOBICARD™ to compete at scale within the rapidly growing digital identity and networking market.“This is the version that begins turning MOBICARD™ into a true revenue-generating platform,” said Joshua Sodaitis, Chairman & CEO of Peer To Peer Network. “We’ve focused on building a system where both users and businesses can participate in the ecosystem—driving growth, engagement, and ultimately revenue.”The Company is currently finalizing development and preparing for submission to major app stores, with launch anticipated within the next 30 days.OutlookThe Company is currently finalizing development and preparing for submission to the Apple App Store and Google Play Store. While no assurances can be given, management anticipates launch within the next 30 days.About Peer To Peer Network (OTC: PTOP)Peer To Peer Network, Inc. (OTC PINK: PTOP) is a technology company developing platforms that enhance communication, transparency, and connectivity between individuals and organizations.For more information, visit https://ptopnetwork.com. Contact Information:Peer To Peer Network, Inc.Investor RelationsEmail: info@freemobicard.comPhone: 617-481-1971Website: www.ptopnetwork.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

George Town, Cayman Islands, Apr 24, 2026 - (ACN Newswire via SeaPRwire.com) -�EQIBank today announced the expansion of its global Banking-as-a-Service (BaaS) platform, strengthening its infrastructure and onboarding capabilities to enable organisations to launch licensed banking services globally in as little as 10 weeks.��EQIBank's BaaS platform allows organisations to offer regulated banking services under their own brand without building or licensing a bank. It supports service delivery across more than 180 countries and over 100 currencies through a single banking infrastructure.Available services include multi-currency accounts, international payments, cards, lending, custody, escrow services, foreign exchange and OTC trading. Digital asset capabilities are fully integrated into the platform, enabling fast crypto-to-fiat and fiat-to-crypto conversions supported by deep liquidity and institutional-grade trading infrastructure.EQIBank provides the banking licence, compliance framework and infrastructure, while partners remain in control of their brand and client relationships.Built on a regulated banking foundation, EQIBank combines global reach with a strong compliance and risk framework. The platform includes integrated anti-money laundering, know-your-customer and transaction monitoring systems, supported by a strong regulatory track record. Its compliance framework is specifically designed to support complex cross-border and digital asset activity at scale, alongside established relationships with global correspondent banking partners."Most organisations don't want to become banks, but they do want to offer banking services as part of their business," said Jason Blick, Chairman of EQIBank. "The challenge has always been regulatory complexity and infrastructure. We remove both barriers. Our platform allows partners to launch quickly, operate globally from day one and deliver services across fiat and digital assets within a fully regulated environment."EQIBank's BaaS platform is designed for organisations with international client bases, including digital asset firms, financial institutions, family offices and other globally focused businesses.Since launching its BaaS offering, EQIBank has onboarded new partners each month, with some partners scaling to over 100,000 users within their first year.About EQIBankEQIBank is a global digital bank providing accounts, payments, cards, custody, lending and investment services to businesses, institutions and high-net-worth clients across more than 180 countries. Through its Banking-as-a-Service platform, EQIBank enables organisations to offer licensed banking services under their own brand using regulated infrastructure and global technology systems.Media enquiriesBrand: EQIBankContact: Media teamWebsite: https://baas.eqibank.com/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Apr 24, 2026 - (ACN Newswire via SeaPRwire.com) - FastX today announces the official launch of its platform, a next-generation exchange built for professional and active traders who require institutional‑grade tools without surrendering custody or control of their assets. FastX goes live globally on 5 May, with traders able to access the platform directly at fastx.co.FastX combines deep on‑chain liquidity, multi‑asset perpetual futures markets, and an advanced copy-trading engine designed to bridge the gap between traditional finance and the decentralized digital asset ecosystem. By leveraging blockchain technology, the platform delivers low‑latency mirroring of trades across major decentralized networks worldwide—while keeping users in full control of their own wallets and risk."FastX was created by traders for traders," said Adelene, Chief Executive Officer of FastX. "We've spent our careers on Wall Street desks and in crypto markets, and we've seen the same problems repeat: opaque execution, misaligned incentives, and copytrading systems that ask users to blindly outsource decisions. FastX is our answer—a decentralised, transparent infrastructure layer where traders keep custody, and technology works to augment, not replace, their edge."Backed by a team of veteran traders with more than 50 years of combined experience across top Wall Street institutions and leading crypto trading firms, FastX is built from the ground up as a decentralised protocol. Users connect their own wallets, maintain self‑custody at all times, and interact with smart contracts that execute trades on‑chain, rather than relying on a centralised broker or custodial exchange.At launch, FastX will offer:Deep, on‑chain liquidity across a wide range of perpetual markets, designed to support serious position sizes with tight spreads and minimal slippage.A fast, intuitive trading interface accessible directly via fastx.co, allowing traders to plug in with their preferred wallet and start trading in minutes.A transparent affiliate and points system that shares a meaningful portion of platform fees with the community and rewards traders and partners who help grow liquidity and volume.The flagship feature of FastX is its next‑generation copytrading system. Unlike traditional social trading products that mirror orders on a single venue with unpredictable delays, FastX's engine is designed to route and synchronise copy trades across major decentralised exchanges, layering those capabilities on top of FastX's own liquidity.The result is a copytrading experience that aims to:Minimise latency between lead and follower execution.Mitigate structural risks such as slippage, desync, and obvious forms of manipulation.Exploit decentralised advantages, such as transparent on‑chain track records and programmable risk controls, without turning the platform into a centralised black box."Copytrading has always been typecast as a blind, autonomous disaster waiting to happen," Adelene added. "FastX takes the opposite stance. We use technology to bring more transparency, not less—on‑chain track records, built‑in risk parameters, and infrastructure that reduces front‑running and execution games wherever possible. Over time, our goal is to layer AI‑driven intelligence on top of this foundation so that users can benefit from advanced analytics and risk management, rather than just 'follow and hope'."FastX is currently seed‑funded by a network of angels deeply embedded in the global crypto trading ecosystem. These backers share a common view that the next generation of markets will be built on open, verifiable rails and that traders deserve better, more transparent instrumentation for expressing and managing risk. FastX is assembling a strong advisory board of experienced traders, market makers, and technologists to guide the exchange through its next phase of growth.As a decentralised protocol, FastX does not take custody of user funds and does not operate as a traditional broker. All positions, liquidations, and fee flows are visible on‑chain, giving traders clear, verifiable insight into how the system behaves under all market conditions."Our vision is simple," said Adelene. "We want professional‑grade perpetuals and intelligent copytrading to live where they belong: on transparent, decentralised infrastructure, not in a black box. Launching FastX on 5 May is the first step. From here, we'll continue to ship faster execution, smarter tooling, and AI‑enhanced copytrading that helps traders survive and thrive in 24/7 markets."Traders can learn more and access the exchange at https://fastx.co.About FastXFastX focuses on building decentralised financial infrastructure and tools for professional traders and sophisticated market participants. The company backs products that prioritise self‑custody, transparency, and robust risk management in rapidly evolving digital asset markets.Media ContactBrand: FastX Perpetuals ExchangeContact: Ella HuangWebsite: https://fastx.co/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.The acceptance of the NDA represents an important milestone for the Group’s ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology (ENT). It also marks another significant milestone in the Group’s research and development progress in the field of type 2 inflammatory diseases. If the Product is successfully approved for marketing, the Group will leverage its strong academic promotion capabilities and extensive commercialization network to accelerate the commercialization of the Product. It is also expected to further enhance the academic brand influence of CMS Vision in the relevant specialty areas and provide new momentum for the Group’s business growth.BIC Potential: Dosing once every 4 weeks; Phase III study met the primary endpoint with a favorable safety profileMG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling pathways of the key type 2 inflammatory cytokines IL-4 and IL-13, thereby exerting immunomodulatory effects. It is being developed for the treatment of type 2 inflammatory diseases, including seasonal allergic rhinitis, asthma, atopic dermatitis (AD), prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Currently marketed anti-IL-4Rα therapies require administration once every two weeks. MG-K10, with its longer half-life, enabling a once-every-four-weeks dosing regimen. It therefore has the potential to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, with the potential to be best-in-class. MG-K10 has met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adult patients with moderate-to-severe seasonal allergic rhinitis. The results of the Phase III study demonstrated that the primary endpoint achieved statistical significance, with significantly superior efficacy compared with the placebo group, and a favorable safety profile.Focusing on Unmet Needs: ~250 million patients; 62% of moderate-to-severe patients remain inadequately controlled; long-acting breakthrough brings new treatment opportunitiesAllergic rhinitis is a chronic inflammatory disease of the nasal mucosa mediated by IgE, with type 2 inflammation as the core pathogenic mechanism. It occurs in susceptible individuals upon exposure to environmental allergens such as pollen and dust mites. In recent years, the prevalence of the disease in China has increased from 11.1% to 17.6%, affecting approximately 250 million people[1], among whom 52.2% are patients with persistent moderate-to-severe disease[2]. The disease burden is significant and has become an important public health issue. Current standard treatments, including intranasal corticosteroids and antihistamines, have notable limitations. 62% of patients with moderate-to-severe disease remain inadequately controlled[3]. Long-term use of intranasal corticosteroids may lead to adverse reactions such as epistaxis[4], while antihistamines are often associated with side effects such as drowsiness[5], indicating significant unmet clinical needs. As a biologic therapy targeting IL-4Rα, MG-K10 can block the type 2 inflammatory pathway at its source. Compared with currently approved biologics targeting the same pathway (which require dosing once every two weeks), MG-K10 achieves a differentiated breakthrough in dosing frequency with its long-acting property allowing administration once every four weeks, thereby significantly extending dosing intervals. This may help improve patient treatment adherence and reduce the time and economic burden associated with frequent hospital visits. The Product has the potential to provide a new treatment option for patients with moderate-to-severe disease who respond poorly to conventional therapies, thereby reducing the individual and socio-economic burden associated with the disease.On 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiary for MG-K10. In accordance with the Agreement and supplementary agreements, the Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon Holdings Limited has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. Cheng L, Chen J, Fu Q, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10:300‑353.2. Zheng, Ming et al. “Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China.” Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.145613. White, P et al. “Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x4. Rosenblut, A et al. “Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.” Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x5. Bernstein, Jonathan A et al. “Allergic Rhinitis: A Review.” JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - The 3rd Smart Lighting Expo and the 17th Hong Kong International Lighting Fair (Spring Edition), organised by the Hong Kong Trade Development Council (HKTDC), successfully concluded today at the Hong Kong Convention and Exhibition Centre. The four-day fairs brought together some 900 exhibitors and attracted some 13,000 buyers from 114 countries and regions for on-site visits and sourcing. Buyer numbers recorded growth, including those from Asian markets such as Malaysia and the Philippines; European markets including France, Germany, the Netherlands, Russia and Türkiye; and North and South American markets, including Brazil, Canada and the US, highlighting Hong Kong’s role as a key global hub for lighting products and technology exchange.Jenny Koo, Deputy Executive Director of the HKTDC, said: "This year’s two lighting fairs attracted industry-leading enterprises who showcased cutting-edge high-performance, smart lighting and sustainable products and solutions. The events also attracted quality buyers from global markets. This helps companies diversify supply chains, explore new markets, and underscores Hong Kong’s strength as an ‘International Exhibition Capital’ which boosts efficient business platforms. The fairs are the preferred platform for the industry to showcase innovation, connect with global buyer networks and accelerate business development.”Survey findings: Respondents were most optimistic about the India and Australia marketsTo keep abreast of the latest industry developments, the HKTDC conducted an on-site survey during the fairs, interviewing 450 exhibitors and buyers. The findings show that overall confidence among exhibitors and buyers in future business development has shown a general increase.Key market outlook and product trend findings:49.1% of respondents expect overall sales to increase in the next 12 to 24 months, while 47.6% expect sales to remain stable.Respondents consider India (73.4%), Australia (71%), ASEAN countries (70.4%), and Japan (68.1%) to be promising or very promising target sales markets for lighting products over the next two years in terms of growth.In terms of new market development, exhibitor respondents are actively exploring Middle East (31.8%), Europe (29.5%), ASEAN countries (23.9%), Latin America (17.6%) and North America (14.8%).In the smart lighting segment, respondents identified home automation and intelligent lighting control systems (48.2%), energy saving lighting control solutions (38.2%), and outdoor smart security lighting systems (31.1%) as having the greatest growth potential over the next two years.Compared with conventional lighting products, respondents indicated that consumers are willing to pay an average premium of 29% for lighting products equipped with smart functions.Scenario-based displays and new zones enhance sourcing effectiveness, with positive trade outcomesThe newly launched “Light Lab” features various scenario-based and immersive designs, integrating lighting products into landscape, sports, cultural and artistic application settings. Shanghai Sansi Electronic Engineering showcased plant clamp lights and compact downlights suitable for museum applications. Guoli Zhu, Deputy Chief Engineer of the company said: “The Light Lab has effectively enhanced the presentation of our products, enabling buyers to more intuitively and swiftly grasp product features and their real-world application scenarios. This has successfully attracted buyers from Argentina, Canada, Germany, India, Japan and the US to visit our booth for in-depth discussions. We expect this to result in orders worth over US$1 million.”The Smart Lighting Expo also debuted the “Smart Display and Stage Lighting & Sound Zone” which displayed a wide range of intelligent display solutions. Industry leader Absen participated in the fair for the first time. Benjamin Tang, Senior Sales Engineer, said: “The new zone has effectively enhanced product visibility, attracting buyers from Eastern Europe, Oceania, North America, South America, and South Asia to our booth. These inquiries came from new clients across key sectors such as cultural tourism and stage engineering. We have also successfully engaged in several promising collaboration discussions with potential clients from the Dominican Republic, Hong Kong and Thailand, further strengthening the company’s market expansion plan. We estimate the value of orders from the expo will amount to US$930,000. Riding on this momentum, we have decided to join the Hong Kong International Lighting Fair (Autumn Edition) this year.”The newly launched “Leisure Lighting Zone” has injected new momentum into the Spring Lighting Fair. Rebecca Seo, CFO of NIZ, a first-time exhibitor from Korea, said: “The fair has provided us with an excellent platform to connect with international buyers. We have successfully connected with buyers from Denmark, Germany, Japan, and the US, and a well-known Japanese homeware retailer has already placed an on-site order. Thanks to the strong traffic generated by the new zone, we expect the fair to bring up to US$70 million in orders for our company this year."Supported by Zhongshan as the Special Partner City, the fairs featured the Zhongshan Guzhen Pavilion and Zhongshan Henglan Pavilion under the Zhongshan Smart Home Zone, presenting the manufacturing strength and competitiveness of the region’s lighting industry while supporting enterprises in “going global”. Merry Liu, Manager of Bairan Lighting, an industrial enterprise above designated size in Henglan, Zhongshan, said: “The two lighting fairs provide Zhongshan enterprises with an efficient ‘go-global’ gateway, enabling us to connect directly with buyers from Europe, the Middle East, South America, and Southeast Asia. This helps drive our products and brand onto the international stage. We expect to achieve US$2 million in sales.”During the fair, the HKTDC organised a buying mission to Zhongshan for the first time, visiting several lighting factories and participating in business matching meetings. This initiative aimed to deepen exchange and cooperation within the Zhongshan lighting supply chain. The visit successfully facilitated several substantive business collaborations; New Zealand buyer Spark100 Ltd established a connection with a Zhongshan lighting supplier, with a potential order value estimated between US$100,000 and US$300,000.This year’s exhibition also attracted buyers from the Middle East. Patrick Zhang, VP of sales of Tecnon Lighting Technology from the Shenzhen Pavilion, stated: “At this year’s fair, a buyer from the United Arab Emirates and a US buyer from a leading women’s fashion brand are likely to become our cooperation partners. We expect to generate US$2 million in sales turnover for our company.”As construction projects in the ASEAN region accelerate, market demand for smart lighting solutions continues to expand. Sambath HK, Manager of RS Decoration from Cambodia, stated, “I travelled here specifically to source lighting products for 14 new commercial building and luxury residential projects. I have already met with over 20 new suppliers and identified two potential partners offering smart street lights, solar lights, and decorative lighting products. I will initially purchase US$100,000 worth of smart street lights.”Driven by the Belt and Road Initiative, urban development in participating countries and regions are in full swing, fuelling a continuous surge in demand for high-efficiency and smart lighting products. Aigerim Beisekina, Supply Manager of Karelz.kz from Kazakhstan, said: “This is our first time visiting the twin lighting fairs, to find reliable suppliers for a solar-powered stadium and sports lighting for three international schools currently under construction in Kazakhstan. Through the Click2Match business matching platform, we have identified three potential suppliers from the Chinese Mainland and plan to purchase lighting equipment valued between US$600,000 and US$900,000.”During the fairs, multiple professional events were held, including the Asian Lighting Conference and the Smart Lighting Solutions Forum. Designers and industry representatives from different regions shared market trends, application cases and technological developments, providing forward-looking market insight for the industry.EXHIBITION+ model sustains post-fair business opportunitiesUnder the hybrid EXHIBITION+ model, the twin lighting fairs combined in-person sourcing with online meetings via the HKTDC’s Click2Match smart business-matching platform and hktdc.com sourcing platform. Click2Match will be available until 30 April to facilitate discussions between exhibitors and buyers around the world.Photo download:  https://bit.ly/42m6sqDThe 3rd Smart Lighting Expo and the 17th Hong Kong International Lighting Fair (Spring Edition), organised by the Hong Kong Trade Development Council (HKTDC), successfully concluded today at the Hong Kong Convention and Exhibition Centre, attracted some 13,000 buyers from 114 countries and regions for on-site visits and sourcing.The newly launched “Light Lab” adopted a series of scenario-based and immersive designs, integrating lighting products directly into landscape, sports, cultural and artistic application settings, enabling buyers to better understand product features and practical applications.At the Spring Lighting Fair, the featured “Hall of Aurora” brought together 120 international and premium lighting brands, attracting numerous global buyers.The Shanghai Pudong Intelligent Lighting Association also returned to the Smart Lighting Expo for the third consecutive year, presenting the “Intelligent Ecosystem & IoT Supply Chain Zone”.As for the Spring Lighting Fair, exhibitors include the Xiamen Pavilion, and newly participating Changzhou Zouqu District Pavilion and Zhejiang Pavilion, further broadening industry exchange.The two fairs gathered numerous renowned brands and industry leaders, including Absen (photo), an LED display provider featured at the NBA All-Stars Games, the FIFA Qatar World Cup and Qatar Doha World Expo, and a Guinness World Record holder; and Shanghai Sansi, which supplies over 60% of the display screens in Times Square, New York.During the fairs, the HKTDC arranged various matching activities to connect buyers and exhibitors. The photo shows buyer Powermep from the UAE in discussion with an exhibitor.During the fairs, the HKTDC organised a buying mission to Zhongshan for the first time, visiting several lighting factories and participating in business matching meetings, strengthening exchange and cooperation within the Zhongshan lighting supply chain.‍The Smart Lighting Solution Forum was held on 21 April. Industry experts shared developments in smart home lighting systems and human-centric lighting for home entertainment as well as discussion of the eco-system of health and connected lighting supply chains.As part of the city’s mega-event economy, the Hong Kong Tourism Board (official exhibition promotion partner) arranged special “Cheung Po Tsai” Victoria Harbour night cruises during the fairs to enhance the business travel experience of convention and exhibition visitors.WebsitesHong Kong International Lighting Fair (Spring Edition): hklightingfairse.hktdc.com/tcSmart Lighting Expo: smartlightingexpo.hktdc.com/tcHKTDC Mediaroom: http://mediaroom.hktdc.com/enMedia enquiriesHKTDC’s Communications & Public Affairs Department:Stanley So Tel: (852) 2584 4049 Email: stanley.hp.so@hktdc.orgNavin Law Tel: (852) 2584 4525  Email: navin.cm.law@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SPRINGVILLE, UT, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - Sisel International�today announced that it has appointed Pamela Ferry as General Manager of Australia and New Zealand as the company accelerates its expansion and transitions to full market operations across the region.Ferry brings more than 20 years of experience in the global direct selling industry, with a focus on international market expansion, distributor growth, and leadership development, including experience supporting the relaunch of underperforming markets and driving renewed growth. Throughout her career, she has held leadership roles focused on building strong teams, developing field leaders, and fostering long-term organizational success. An experienced presenter, trainer, and events professional, Ferry is recognized for her ability to connect with audiences and translate strategy into practical field execution. Her strengths in relationship building and education position her to play a key role in developing Sisel's distributor network and establishing a strong foundation in the region.The appointment comes at a pivotal stage as Sisel expands into the Australian market, with a focus on building infrastructure, enabling�distributor growth, and introducing its science-driven wellness solutions to new audiences. Ferry will lead efforts to develop market operations, strengthen field support, and drive sustainable growth across Australia and New Zealand."Australia represents an important opportunity for Sisel as we continue our international expansion," said Tom Mower Jr., CEO and Co-Founder of Sisel International. "Pamela brings not only deep industry experience, but a proven ability to develop leaders and build strong distributor networks. Her leadership will be instrumental as we establish a long-term presence in the region."About Sisel International Sisel International is a global health and wellness company dedicated to developing high-quality, science-driven products designed to support healthier living. Co-founded by Tom Mower Sr. and led by CEO Tom Mower Jr., Sisel creates supplements, personal care, home care, and wellness solutions formulated without harmful or unnecessary ingredients. Guided by its founding principles, the company is committed to innovation, safety, and quality while empowering individuals to pursue health, longevity, and personal success worldwide.Media Contact:Sisel InternationalMarketing TeamEmail:�marketing@sisel.netWebsite: www.sisel.netSOURCE: Sisel International Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

开曼群岛乔治敦, 2026年4月23日 - (亚太商讯 via SeaPRwire.com) - GA Ventures Ltd 今日宣布正式推出FastX。这是一款专为专业及活跃交易者打造的下一代交易所，旨在提供机构级工具的同时，确保用户无需放弃对资产的托管或控制权。FastX将于5月 5日在全球上线，交易者可直接访问fastx.co进入平台。FastX结合了深度链上流动性、多资产 永续期货市场以及先进的跟单交易引擎，旨在架起传统金融与去中心化数字资产生态系统之间的桥梁。通过利用区块链技术，平台可在全球主要去中心化网络上实现低延迟交易镜像，同时让用户始终完全掌控自己的钱包和风险。"FastX由交易员为交易员而建，"FastX 首席执行官 Adelene 表示。"我们的职业生涯遍布华尔街交易所和加密市场，也反复看到同样的问题：执行不透明、激励错位，以及要求用户盲目外包决策的跟单系统。FastX 是我们的答案 - 一个去中心化、透明的基础设施层，交易员保留托管权，技术用于增强而非取代他们的优势。"FastX 拥有一支资深交易员团队，成员在顶级华尔街机构和领先加密交易公司拥有超过 50 年综合经验。FastX 从底层构建为去中心化协议。用户连接自己的钱包，始终保持自托管，并通过智能合约在链上执行交易，而非依赖中心化经纪商或托管交易所。发布时，FastX将提供：- 覆盖广泛永续市场的深度链上流动性，支持大额头寸，并尽量保持更小的价差与更低的滑点。- 可通过 fastx.co 直接访问的快速直观交易界面，交易者可接入常用钱包并在数分钟内开始交易。- 透明的联盟与积分体系，与社区分享平台费用中的重要部分，并奖励帮助提升流动性与交易量的交易者及合作伙伴。FastX 的旗舰功能是新一代跟单交易系统。不同于仅在单一场所镜像订单、且延迟不可预测的传统社交交易产品，FastX 引擎可在主要去中心化交易所之间路由并同步跟单交易，并将这些能力叠加在 FastX 自有流动性之上。该跟单交易体验旨在：- 降低主策略交易员与跟随交易员之间的执行延迟。- 缓解滑点、不同步及明显操纵行为等结构性风险。- 发挥去中心化优势，例如透明的链上历史记录和可编程风险控制，同时避免把平台做成中心化黑箱。"跟单交易长期被视为一场盲目且高风险的自动化行为，"Adelene 补充道。"FastX 采取完全相反的路径。我们用技术带来更多透明度——链上记录、内置风险参数，以及尽可能减少抢跑和执行博弈的基础设施。随着发展，我们将在此基础上叠加人工智能驱动的能力，让用户真正受益于高级分析与风险管理，而不是只会‘跟随并等待结果’。"FastX 目前由深耕全球加密交易生态的天使投资人网络提供种子轮资金。这些支持者有共同判断：下一代市场将建立在开放、可验证的基础设施之上，交易员应获得更好、更透明的工具来表达和管理风险。GA Ventures Ltd 与 FastX 正在组建由资深交易员、做市商及技术专家组成的顾问委员会，推动交易所进入下一阶段增长。作为去中心化协议，FastX 不托管用户资金，也不以传统经纪商模式运营。所有头寸、清算和费用流都可在链上查看，让交易员在各种市场环境下都能对系统行为获得清晰、可验证的认知。"我们的愿景很简单，"Adelene 表示。"我们希望专业级永续交易与智能跟单交易，运行在它们真正应在的地方：透明的去中心化基础设施，而不是黑箱。5 月 5 日上线 FastX 只是第一步。接下来我们将持续交付更快执行、更智能工具，以及由人工智能增强的跟单交易能力，帮助交易员在全天候市场中生存并增长。"交易员可以通过 https://fastx.co 了解更多信息并访问交易所。关于 GA Ventures LtdGA Ventures Ltd注册于开曼群岛，专注于为专业交易员和成熟市场参与者构建去中心化金融基础设施与工具。公司支持的产品优先强调在快速演进的数字资产市场中实现自托管、透明度和稳健风险管理。媒体联系品牌：FastX Perpetuals Exchange（GA Ventures Ltd）邮箱：support@fastx.co 联系人：Ella Huang网站：https://fastx.co/ Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - FastX today announces the official launch of its platform, a next-generation exchange built for professional and active traders who require institutional‑grade tools without surrendering custody or control of their assets. FastX goes live globally on 5 May, with traders able to access the platform directly at fastx.co.FastX combines deep on‑chain liquidity, multi‑asset perpetual futures markets, and an advanced copy-trading engine designed to bridge the gap between traditional finance and the decentralized digital asset ecosystem. By leveraging blockchain technology, the platform delivers low‑latency mirroring of trades across major decentralized networks worldwide—while keeping users in full control of their own wallets and risk."FastX was created by traders for traders," said Adelene, Chief Executive Officer of FastX. "We've spent our careers on Wall Street desks and in crypto markets, and we've seen the same problems repeat: opaque execution, misaligned incentives, and copytrading systems that ask users to blindly outsource decisions. FastX is our answer—a decentralised, transparent infrastructure layer where traders keep custody, and technology works to augment, not replace, their edge."Backed by a team of veteran traders with more than 50 years of combined experience across top Wall Street institutions and leading crypto trading firms, FastX is built from the ground up as a decentralised protocol. Users connect their own wallets, maintain self‑custody at all times, and interact with smart contracts that execute trades on‑chain, rather than relying on a centralised broker or custodial exchange.At launch, FastX will offer:Deep, on‑chain liquidity across a wide range of perpetual markets, designed to support serious position sizes with tight spreads and minimal slippage.A fast, intuitive trading interface accessible directly via fastx.co, allowing traders to plug in with their preferred wallet and start trading in minutes.A transparent affiliate and points system that shares a meaningful portion of platform fees with the community and rewards traders and partners who help grow liquidity and volume.The flagship feature of FastX is its next‑generation copytrading system. Unlike traditional social trading products that mirror orders on a single venue with unpredictable delays, FastX's engine is designed to route and synchronise copy trades across major decentralised exchanges, layering those capabilities on top of FastX's own liquidity.The result is a copytrading experience that aims to:Minimise latency between lead and follower execution.Mitigate structural risks such as slippage, desync, and obvious forms of manipulation.Exploit decentralised advantages, such as transparent on‑chain track records and programmable risk controls, without turning the platform into a centralised black box."Copytrading has always been typecast as a blind, autonomous disaster waiting to happen," Adelene added. "FastX takes the opposite stance. We use technology to bring more transparency, not less—on‑chain track records, built‑in risk parameters, and infrastructure that reduces front‑running and execution games wherever possible. Over time, our goal is to layer AI‑driven intelligence on top of this foundation so that users can benefit from advanced analytics and risk management, rather than just 'follow and hope'."FastX is currently seed‑funded by a network of angels deeply embedded in the global crypto trading ecosystem. These backers share a common view that the next generation of markets will be built on open, verifiable rails and that traders deserve better, more transparent instrumentation for expressing and managing risk. FastX is assembling a strong advisory board of experienced traders, market makers, and technologists to guide the exchange through its next phase of growth.As a decentralised protocol, FastX does not take custody of user funds and does not operate as a traditional broker. All positions, liquidations, and fee flows are visible on‑chain, giving traders clear, verifiable insight into how the system behaves under all market conditions."Our vision is simple," said Adelene. "We want professional‑grade perpetuals and intelligent copytrading to live where they belong: on transparent, decentralised infrastructure, not in a black box. Launching FastX on 5 May is the first step. From here, we'll continue to ship faster execution, smarter tooling, and AI‑enhanced copytrading that helps traders survive and thrive in 24/7 markets."Traders can learn more and access the exchange at https://fastx.co.About FastXFastX focuses on building decentralised financial infrastructure and tools for professional traders and sophisticated market participants. The company backs products that prioritise self‑custody, transparency, and robust risk management in rapidly evolving digital asset markets.Media ContactBrand: FastX Perpetuals ExchangeContact: Ella HuangWebsite: https://fastx.co/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com